Inhibitors of diacvlglvcerol O-acvltransferase type 1 enzyme Field of the Invention Compounds that are inhibitors of the diacylglycerol O-acyltransferase type 1 (DGAT-1) enzyme are disclosed. Methods of using such compounds to inhibit the activity of diacylglycerol O-acyltransferase type 1 and pharmaceutical compositions including such compounds are also encompassed. Background of the Invention Triacylglycerides represent the major form of energy storage in eukaryotes, and disorders or imbalance in triacylglycerides metabolism are implicated in the pathogenesis and increased risk for obesity, insulin resistance, type II diabetes, nonalcoholic fatty liver disease and coronary heart disease (Lewis, et al., Endocrine Reviews 23:201, 2002). Storage of excess triacylglycerides in lean tissues, such as liver, muscle, and other peripheral tissues, leads to lipid-induced dysfunction in those tissues; thus, reducing fat accumulation in nonadipose sites appears to be of benefit in the treatment of lipotoxicity (Unger, R. H. Endocrinology, 144: 5159-5165, 2003). Accumulation of excess triacylglycerides in white adipose tissue (WAT) leads to obesity, a condition that is associated with decreased life span, type II diabetes, coronary artery disease, hypertension, stroke, and the development of some cancers (Grundy, S. M. Endocrine 13(2): 155-165, 2000). Obesity is a chronic disease that is highly prevalent in modern society and current pharmacological treatment options are limited, creating a need to develop pharmaceutical agents for the treatment of obesity that are safe and effective. Diacylglycerol O-acyltransfereases (DGATs) are membrane-bound enzymes that catalyze the terminal step of triacylglycerides biosynthesis. Two enzymes that display DGAT activity have been characterized: DGAT-1 (diacylglycerol O-acyltransferase type 1) (U.S. Pat. No. 6,100,077; Cases, et al., Proc. Nat. Acad. Sci. 95:13018-13023, 1998) and DGAT-2 (diacylglyerol O-acyltransferase type 2) (Cases, et al., J. Biol. Chem. 276:38870-38876, 2001). DGAT-1 and DGAT-2 share only 12% sequence identity. Significantly, DGAT-1 null mice are resistant to diet-induced obesity and have increased sensitivity to insulin and leptin (Smith, et al., Nature Genetics 25:87-90, 2000; Chen and Farese, Trends Cardiovasc Med. 10:188, 2000; Chen et al., J. Clin. Invest. 109:10049, 2002). DGAT-1 deficient mice are protected against hepatic steatosis, demonstrate increased energy expenditure, and decreased levels of tissue triacylglycerides. In addition to improved triacylglycerides metabolism, DGAT-1 deficient mice also have improved glucose metabolism, with lower glucose and insulin levels following a glucose load, in comparison to wild-type mice. Partial DGAT-1 deficiency in heterozygous DGAT-1+/- animals is sufficient to deliver an intermediate phenotype on body weight, adiposity, and insulin and glucose metabolism when compared to wild type and homozyogous littermates (Chen and Farese, Arterioscler. Thromb. Vase. Biol. 25:482-486, 2005), and small molecule DGAT-1 inhibitors have been reported to induce weight loss in diet-induced obese (DIO) mice (US 2004/0224997). The phenotypes of DGAT-1 deficient mice, and the pharmacological activity reported with DGAT-1 inhibitors suggests that the discovery of small molecules that effectively block the conversion of diacylglycerol to triacylglycerides by inhibiting the DGAT-1 enzyme can have utility in the treatment of obesity and other diseases associated with triacylglycerides imbalance. Summary of the Invention One aspect of the invention is directed towards compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, (Formula Removed) wherein G1 is phenyl or monocyclic heteroaryl, each of which is optionally further substituted with 1,2, 3, or 4 substituents as represented by T; G2 is phenyl or monocyclic heteroaryl, each of which is optionally further substituted with 1,2, 3, or 4 substituents as represented by T; T, at each occurrence, is independently selected from the group including, but not limited to, alkyl, alkenyl, alkynyl, halogen, -CN, -N02, -OR1, -OC(O)(R2), -N^XR1), -NtR^CXOXR1), -NCR^-CCOXXR1), -N(Rw)-C(O)N(Rw)(R1), -N(Rw)-S(O)2(R2), -C(O)0(R1), -C(O)N(Rw)(R1), -C(O)R\ -SR1, -S(O)R2, -S(O)2R2, -S(O)2N(Rw)(R1), -(CRaRVCN, -(CRaRb)r-N02, -(CR^VOR1, -(CRaRV0C(O)(R2), -(CRaRb)r-N(Rw)(R1), -(CR^VNCR^CXOXR1), -(CR^YNCR^-QOMR1), -(CR'RVNtR^-CXOMR^tR1), -(CRaRb)r-N(Rw)-S(O)2(R2), -(CR'ftVCCOPCR1), -(CR^VCCOMR^CR1), -(CRaRVC(O)R\ -(CRaRVSR\ -(CRaRVS(O)R2, -(CRaRVS(O)2R2, -(CR^Vs^zNCR^CR1), and haloalkyl; or two of the adjacent substituents T, together with the carbon atoms to which they are attached, form a monocyclic ring selected from the group including, but not limited to, phenyl, heterocycle and heteroaryl, wherein each ring is optionally further substituted with 1, 2 or 3 substituents selected from the group including, but not limited to, oxo, alkyl, alkenyl, alkynyl, halogen, -CN, -N02) -OR1, -OC(O)(R2), -N(RWXR'), -NCR^CCOXR1), -N(Rw)-C(O)0(R1), -N(Rw)-C(O)N(Rw)(R1), -N(Rw)-S(O)2(R2), -C(O)0(R1), -C(O)N(Rw)(R1), -C(O)R1, -SR1, -S(O)R2, -S(O)2R2, -S^zNCR^R1), -(CRaRVCN, -(CRaRYN02) -(CR^VOR1, -(CRaRVoc(oxR2), -(CR^VNCR^CR1), -(CR'RVNCR^CCOXR1), -(CRaRb)r-N(Rw)-C(O)0(R1), -(CRaRb)r-N(Rw)-C(O)N(RwXR1), -(CRaRb)I-N(Rw)-S(O)2(R2), -(CR^VC^OCR1), -(CR^VCXCONCR^CR1), -(CRaRVC(O)R\ -(CR'RVSR1, -(CRaRb)r-S(O)R2, -(CRaRVS(O)2R2, -(CR^VSCO^N^XR1), and haloalkyl; G3 is formula (a) or formula (b) (Formula Removed) W1 is -C(R3)(R4)- or -C(R3)(R4)-C(R3)(R4)-, and W2 is -C(R7)- or N; or W1 is N(H), N(alkyl), 0, S(O), or S(O)2, and W2 is-C(R7)-; W3isN(H),N(alkyl),orO; W4 is -C(R3)(R4)- or-C(R3XR4)-C(R3)(R4)-; R and R , at each occurrence, are independently hydrogen or C1-6 alkyl; R5andR6 are independently hydrogen or C1-6 alkyl; or R5 and R6, together with the carbon to which they are attached, is C(=0); R , at each occurrence, is independently hydrogen, C1-6 alkyl or -C(O)OH; Rc and R .together with the carbon atom to which they are attached, is a 3- to 6-membered cycloalkyl or a monocyclic heterocycle of formula (c); (Formula Removed) wherein 1, 2, 3, or 4 hydrogen atoms attached to the ring carbon of the cycloalkyl and the monocyclic heterocycle are optionally replaced with radicals selected from the group including, but not limited to, alkyl, halogen, -CN, haloalkyl, -C(O)0(R8), -C(O)N(R8)(R9), -(CReRf)t-C(O)0(R8), and -(CReRf)rC(O)N(R8XR9); W5is-CH2-or-CH2-CH2-; W6 is O, S, S(O), S(O)2, N(RX), -C(O)N(Ry)- or -N(Ry)C(O)-; wherein RX is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl, cycloalkenylalkyl, arylalkyl, heteroarylalkyl, heterocyclealkyl, -C(O)0(Rz), -C(O)Rz, or -C(O)N(Rw)(Rm); Ry and Rm, at each occurrence, are each independently hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycle, arylalkyl, cycloalkylalkyl, cycloalkenylalkyl, heteroarylalkyl, or heterocyclealkyl; Rz, at each occurrence, is independently alkyl, haloalkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycle, arylalkyl, cycloalkylalkyl, cycloalkenylalkyl, heteroarylalkyl, or heterocyclealkyl; R8 and R9, at each occurrence, are independently hydrogen, alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycle, haloalkyl, arylalkyl, cycloalkylalkyl, cycloalkenylalkyl, heteroarylalkyl, or heterocyclealkyl; or R8 and R9, together with the nitrogen atom to which they are attached, form a heterocycle ring, optionally further substituted with 1, 2 or 3 substituents selected from the group consisting of alkyl, halogen, and haloalkyl; L1 is O, N(H), or N(alkyl); and X is -30% reduction in plasma triglycerides in drug treated animals (measured one hour after the administration of corn oil bolus) relative to vehicle- treated control animals. In this model, representative compounds produced significant reductions in plasma triglycerides, relative to vehicle-treated control animals. Compounds of the present invention and the pharmaceutically acceptable salts are useful as therapeutic agents. Accordingly, an embodiment of this invention includes a method of treating the various conditions in a subject in need thereof (including mammals) which includes administering to the subject an amount of the compound of formula (I), (II), or (III), or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, that is effective in treating the target condition, or a pharmaceutical composition including the same. Another aspect of the present invention provides a method of treating, delay or prevention of various conditions in a patient (such as mammal, preferably human) that are mediated by DGAT-1, which includes administering to the patient a compound of formula (I), (II), or (III), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug thereof, or a pharmaceutical composition including the same. Another aspect of the present invention provides methods for the prevention, delay or treatment of obesity and inducing weight loss in an individual which includes administering to the individual a compound of the invention, or its pharmaceutically acceptable salt, prodrug, salt of a prodrug thereof, or a pharmaceutical composition including the same. Yet another aspect of the invention provides a method for preventing weight gain in an individual by administering at least one compound of the invention, or its pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, in an amount that is sufficient to prevent weight gain. The present invention also relates to the use of the compounds of this invention for the treatment of obesity-related diseases including associated dyslipidemia and other obesity-and overweight-related complications such as, for example, cholesterol gallstones, gallbladder disease, gout, cancer (e.g., colon, rectum, prostate, breast, ovary, endometrium, cervix, gallbladder, and bile duct), menstrual abnormalities, infertility, polycystic ovaries, osteoarthritis, and sleep apnea, as well as for a number of other pharmaceutical uses associated therewith, such as the regulation of appetite and food intake, dyslipidemia, hypertriglyceridemia, metabolic syndrome or Syndrome X, type 2 diabetes (non-insulin-dependent diabetes), atherosclerotic diseases such as heart failure, hyperlipidemia, hypercholesteremia, low HDL levels, hypertension, cardiovascular disease (including atherosclerosis, coronary heart disease, coronary artery disease, and hypertension), cerebrovascular disease such as stroke, and peripheral vessel disease. The compounds of this invention can also be useful for treating physiological disorders related to, for example, regulation of insulin sensitivity, inflammatory response, liver steatosis, elevated liver triacylglycerides, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, plasma triacylglycerides, HDL, LDL and cholesterol levels and the like. Metabolic syndrome is characterized by a group of metabolic risk factors in one person. Such factors include, but are not limited to, abdominal obesity, atherogenic dyslipidemia (blood fat disorders such as high triglycerides, low HDL cholesterol and high LDL cholesterol), elevated blood pressure, insulin resistance (or glucose intolerance), prothrombotic state (e.g. high fibrinogen or plasminogen activator inhibitor-1 in the blood), and proinflammatory state (e.g. elevated C-reactive protein in the blood). In one embodiment, the present invention provides methods of treating the above listed disorders wherein the methods include the step of administering to a subject in need thereof one or more of the compound of the invention, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition including the same. The compounds of this invention, or pharmaceutical acceptable salts thereof, or pharmaceutical compositions including the same, are also useful in lowering plasma triglycerides level. Thus, in one embodiment, the present invention provides a method for lowering plasma triglycerides in a subject (including mammal) in need thereof, wherein the method includes the step of administering to the subject in need thereof one or more of the compound of invention, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition including the same. The term "treatment" or "treating" includes any process, action, application, therpy, or the like, wherein a subject, including human, is provided medical aid with the object of improving the subject's condition, directly or indirectly, or slowing the progression of a condition or disorder in the subject. Compounds of the invention, or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combination thereof, can be administered alone or in combination (i.e. coadministered) with one or more additional pharmaceutical agents. Combination therapy includes administration of a single pharmaceutical dosage formulation containing one or more of the compounds of invention, or pharmaceutically acceptable salts, prodrug, salts of prodrugs thereof, and one or more additional pharmaceutical agents, as well as administration of the compounds of invention, or pharmaceutically acceptable salts, prodrug, salts of prodrugs thereof, and each additional pharmaceutical agent, in its own separate pharmaceutical dosage formulation. For example, a compound of formula (I), (II), or (III), or a pharmaceutically acceptable salts, prodrugs, salts of prodrugs thereof, and one or more additional pharmaceutical agents, can be administered to the patient together, in a single oral dosage composition having a fixed ratio of each active ingredient, such as a tablet or capsule; or each agent can be administered in separate oral dosage formulations. Where separate dosage formulations are used, compounds of the invention (or pharmaceutical salts, prodrugs, or salts of prodrugs thereof) and one or more additional pharmaceutical agents can be administered at essentially the same time (e.g., concurrently) or at separately staggered times (e.g., sequentially). For example, the compounds of the invention (or pharmaceutical salts, prodrugs, or salts of prodrugs thereof) can be used in combination with one of more of the following pharmaceutical agents, including, but not limited to, anti-obesity drugs including (3-3 agonists such as CL-316,243; CB-1 antagonists and/or inverse agonsists (for example, rimonabant); neuropeptide Y5 inhibitors; appetite suppressants, such as, for example, sibutramine (Meridia); MCHrl antagonists and lipase inhibitors, such as, for example, orlistat (Xenical), and a drug compound that modulates digestion and/or metabolism such as drugs that modulate thermogenesis, lipolysis, gut motility, fat absorption, and satiety. In addition, compounds of the invention (or pharmaceutical salts, prodrugs, or salts of prodrugs thereof) can be administered in combination with one or more of the following pharmaceutical agents including PPAR ligands (agonists, antagonists), insulin secretagogues (for example, sulfonylurea drugs and non-sulfonylurea secretagogues), a- glucosidase inhibitors, insulin sensitizers, hepatic glucose output lowering compounds, and insulin and insulin derivatives. Such agents can be administered prior to, concurrently with, or following administration of the compounds of the invention. Insulin and insulin derivatives include both long and short acting forms and formulations of insulin. PPAR ligands can include agonists and/or antagonists of any of the PPAR receptors or combinations thereof. For example, PPAR ligands can, include ligands of PPAR-a, PPAR-y, PPAR-8 or any combination of two or three of the receptors of PPAR. PPAR ligands include, for example, rosiglitazone, troglitazone, and pioglitazone. Sulfonylurea drugs include, for example, glyburide, glimepiride, chlorpropamide, tolbutamide, and glipizide, α-glucosidase inhibitors include acarbose, miglitol, and voglibose. Insulin sensitizers include PPAR-y agonists such as the glitazones (e.g., troglitazone, pioglitazone, englitazone, MCC-555, rosiglitazone, and the like) and other thiazolidinedione and non- thiazolidinedione compounds; biguanides such as metformin and phenformin; protein tyrosine phosphatase-1B (PP-1B) inhibitors; dipeptidyl peptidase IV (DPP-IV) inhibitors (for example, sitagliptin), and llbeta-HSD inhibitors. Hepatic glucose output lowering compounds include glucagon anatgonists and metformin, such as Glucophage and Glucophage XR. Insulin secretagogues include sulfonylurea and non- sulfonylurea drugs: GLP-1, GIP, PACAP, secretin, and derivatives thereof; nateglinide, meglitinide, repaglinide, glibenclamide, glimepiride, chlorpropamide, glipizide. GLP-1 includes derivatives of GLP-1 with longer half-lives than native GLP-1, such as, for example, fatty-acid derivatized GLP-1 and exendin. Compounds of the invention (or pharmaceutical salts, prodrugs, or salts of prodrugs thereof) can also be used in methods of the invention in combination with one or more pharmaceutical agents including, but are not limited to, HMG-CoA reductase inhibitors, nicotinic acid (for example, Niaspan), fatty acid lowering compounds (e.g., acipimox); lipid lowering drugs (e.g., stanol esters, sterol glycosides such as tiqueside, and azetidinones such as ezetimibe), ACAT inhibitors (such as avasimibe), bile acid sequestrants, bile acid reuptake inhibitors, microsomal triacylglycerides transport inhibitors, and fibric acid derivatives. HMG-CoA reductase inhibitors include, for example, statin such as lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, itavastatin, cerivastatin, and ZD-4522. Fibric acid derivatives include, for example, clofibrate, fenofibrate, bezafibrate, ciprofibrate, beclofibrate, etofibrate, and gemfibrozil. Sequestrants include, for example, cholestyramine, colestipol, and dialkylaminoalkyl derivatives of a cross-linked dextran. Compounds of the invention (or pharmaceutical salts, prodrugs, or salts of prodrugs thereof) can also be used in combination with anti- hypertensive drugs, such as, for example, P-blockers and ACE inhibitors. Examples of additional anti-hypertensive agents for use in combination with the compounds of the present invention include calcium channel blockers (L-type and T-type; e.g., diltiazem, verapamil, nifedipine, amlodipine and mybefradil), diuretics (e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendrofiumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene, amiloride, spironolactone), renin inhibitors, ACE inhibitors (e.g., captopril, zofenopril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril, lisinopril), AT-1 receptor antagonists (e. g., losartan, irbesartan, valsartan), ET receptor antagonists (e.g., sitaxsentan, atrsentan, neutral endopeptidase (NEP) inhibitors, vasopepsidase inhibitors (dual NEP-ACE inhibitors) (e.g., omapatrilat and gemopatrilat), and nitrates. The compounds of this invention can also be co-administered with an incretin mimetic such as, but not limited to, exenatide. The compounds of this invention (or pharmaceutical salts, prodrugs, or salts of prodrugs thereof) can be utilized to achieve the desired pharmacological effect by administration to a subject in need thereof in an appropriately formulated pharmaceutical composition. A subject, for example, can be a mammal, including human, in need of treatment for a particular condition or disease. Therefore the present invention includes pharmaceutical compositions which are included of a therapeutically effective amount of a compound (or pharmaceutical salts, prodrugs, or salts of prodrugs thereof) identified by the methods described herein, in combination with a pharmaceutically acceptable carrier. The compounds identified by the methods described herein can be administered with a pharmaceutically acceptable carrier using any effective conventional dosage unit forms, for example, immediate and timed release preparations, orally, parenterally, topically, or the like. The pharmaceutical compositions can be formulated for oral administration in solid or liquid form, for parenteral injection or for rectal administration. The term "pharmaceutically acceptable carrier" as used herein, means a non-toxic, solid, semi-solid or liquid filler, diluent, encapsulating material, or formulation auxiliary of any type. Examples of therapeutically suitable excipients include sugars; cellulose and derivatives thereof; oils; glycols; solutions; buffering, coloring, releasing, coating, sweetening, flavoring, and perfuming agents; and the like. These therapeutic compositions can be administered parenterally, intracisternally, orally, rectally, intraveneously, or intraperitoneally. Liquid dosage forms for oral administration of the present compounds include formulations of the same as emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the compounds, the liquid dosage forms can contain diluents and/or solubilizing or emulsifying agents. Besides inert diluents, the oral compositions can include wetting, emulsifying, sweetening, flavoring, and perfuming agents. Injectable preparations of the present compounds include sterile, injectable, aqueous and oleaginous solutions, suspensions or emulsions, any of which can be optionally formulated with parenterally suitable diluents, dispersing, wetting, or suspending agents. These injectable preparations can be sterilized by filtration through a bacterial-retaining filter or formulated with sterilizing agents that dissolve or disperse in the injectable media. Inhibition of DGAT-1 by the compounds of the present invention can be delayed by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compounds depends upon their rate of dissolution, which, in turn, depends on their crystallinity. Delayed absorption of a parenterally administered compound can be accomplished by dissolving or suspending the compound in oil. Injectable depot forms of the compounds can also be prepared by microencapsulating the same in biodegradable polymers. Depending upon the ratio of compound to polymer and the nature of the polymer employed, the rate of release can be controlled. Depot injectable formulations are also prepared by entrapping the compounds in liposomes or microemulsions that are compatible with body tissues. Solid dosage forms for oral administration of the present compounds include capsules, tablets, pills, powders, and granules. In such forms, the compound is mixed with at least one inert, therapeutically suitable excipient such as a carrier, filler, extender, disintegrating agent, solution retarding agent, wetting agent, absorbent, or lubricant. With capsules, tablets, and pills, the excipient can also contain buffering agents. Suppositories for rectal administration can be prepared by mixing the compounds with a suitable non-irritating excipient that is solid at ordinary temperature but fluid in the rectum. The present compounds can be micro-encapsulated with one or more of the excipients discussed previously. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric and release-controlling. In these forms, the compounds can be mixed with at least one inert diluent and can optionally include tableting lubricants and aids. Capsules can also optionally contain opacifying agents that delay release of the compounds in a desired part of the intestinal tract. Transdermal patches have the added advantage of providing controlled delivery of the present compounds to the body. Such dosage forms are prepared by dissolving or dispensing the compounds in the proper medium. Absorption enhancers can also be used to increase the flux of the compounds across the skin, and the rate of absorption can be controlled by providing a rate controlling membrane or by dispersing the compounds in a polymer matrix or gel. The compounds of the invention can be used in the form of pharmaceutically acceptable salts, esters, or amides derived from inorganic or organic acids. The term "pharmaceutically acceptable salts, esters and amides," as used herein, include salts, zwitterions, esters and amides of compounds of disclosed herein which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use. Pharmaceutically acceptable salts are well-known in the art. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group of the compounds with a suitable acid. Representative salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, isethionate, fumarate, lactate, malate, maleate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, oxalate, pivalate, propionate, succinate, tartrate, trichloroacetic, trifluoroacetic, glutamate, para-toluenesulfonate, undecanoate, hydrochloric, hydrobromic, sulfuric, phosphoric, and the like. The amino groups of the compounds can also be quaternized with alkyl chlorides, bromides, and iodides such as methyl, ethyl, propyl, isopropyl, butyl, lauryl, myristyl, stearyl, and the like. Basic addition salts can be prepared during the final isolation and purification of the present compounds by reaction of a carboxyl group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation such as lithium, sodium, potassium, calcium, magnesium, or aluminum, or an organic primary, secondary, or tertiary amine. Quaternary amine salts derived from methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributlyamine, pyridine, N,N-dimethylaniline, N- methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N- dibenzylphenethylamine, 1-ephenamine, and N,N'-dibenzylethylenediamine, ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine, and the like, are contemplated as being within the scope of the present invention. The term "pharmaceutically acceptable ester," as used herein, refers to esters of compounds of the invention which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Examples of pharmaceutically acceptable, non-toxic esters of the invention include C1-e alkyl esters and C5-7 cycloalkyl esters, although C1-4 alkyl esters are preferred. Esters of the compounds of the invention can be prepared according to conventional methods. Pharmaceutically acceptable esters can be appended onto hydroxy groups by reaction of the compound that contains the hydroxy group with acid and an alkylcarboxylic acid such as acetic acid, or with acid and an arylcarboxylic acid such as benzoic acid. In the case of compounds containing carboxylic acid groups, the pharmaceutically acceptable esters are prepared from compounds containing the carboxylic acid groups by reaction of the compound with base such as triethylamine and an alkyl halide, alkyl triflate, for example with methyl iodide, benzyl iodide, cyclopentyl iodide. They also can be prepared by reaction of the compound with an acid such as hydrochloric acid and an alkylcarboxylic acid such as acetic acid, or with acid and an arylcarboxylic acid such as benzoic acid. The term "pharmaceutically acceptable amide," as used herein, refers to non-toxic amides of the invention derived from ammonia, primary C1-6 alkyl amines and secondary C1-6 dialkyl amines. In the case of secondary amines, the amine can also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C1.3 alkyl primary amides and C1.2 dialkyl secondary amides are preferred. Amides of the compounds of the invention, can be prepared according to conventional methods. Pharmaceutically acceptable amides can be prepared from compounds containing primary or secondary amine groups by reaction of the compound that contains the amino group with an alkyl anhydride, aryl anhydride, acyl halide, or aroyl halide. In the case of compounds containing carboxylic acid groups, the pharmaceutically acceptable esters are prepared from compounds containing the carboxylic acid groups by reaction of the compound with base such as triethylamine, a dehydrating agent such as dicyclohexyl carbodiimide or carbonyl diimidazole, and an alkyl amine, dialkylamine, for example with methylamine, diethylamine, piperidine. They also can be prepared by reaction of the compound with an acid such as sulfuric acid and an alkylcarboxylic acid such as acetic acid, or with acid and an arylcarboxylic acid such as benzoic acid under dehydrating conditions as with molecular sieves added. The composition can contain a compound of the invention in the form of a pharmaceutically acceptable prodrug. The term "pharmaceutically acceptable prodrug" or "prodrug" as used herein, represents those prodrugs of the compounds of the invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use. Prodrugs of the invention can be rapidly transformed in vivo to a parent compound of the invention, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987). Disorders that can be treated or prevented in a patient by administering to the patient, a therapeutically effective amount of compound (or pharmaceutical salts, prodrugs, or salts of prodrugs thereof) of the present invention in such an amount and for such time as is necessary to achieve the desired result. The term "therapeutically effective amount," refers to a sufficient amount of a compound of the invention to effectively ameliorate disorders by inhibiting DGAT-1 at a reasonable benefit/risk ratio applicable to any medical treatment. The specific therapeutically effective dose level for any particular patient can depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the compound employed; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, rate of excretion; the duration of the treatment; and drugs used in combination or coincidental therapy. The total daily dose of the compounds of the present invention necessary to inhibit the action of DGAT-1 in single or divided doses can be in amounts, for example, from about 0.01 to 50 mg/kg body weight. In a more preferred range, compounds of the present invention inhibit the action of DGAT-1 in a single or divided doses from about 0.05 to 25 mg/kg body weight. Single dose compositions can contain such amounts or submultiple doses thereof of the compounds of the present invention to make up the daily dose. In general, treatment regimens include administration to a patient in need of such treatment from about 1 mg to about 1000 mg of the compounds per day in single or multiple doses. The compounds identified by the methods described herein can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutical agents where the combination causes no unacceptable adverse effects. For example, the compounds of this invention can be combined with anti-obesity, or with known antidiabetic or other indication agents, and the like. Thus, the present invention also includes pharmaceutical compositions which are made of a therapeutically effective amount of a compound identified by the methods described herein, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, and one or more pharmaceutical agents as disclosed hereinabove. The compounds and processes of the present invention are better understood by reference to the following examples, which are intended as an illustration of and not a limitation upon the scope of the invention. Further, all citations herein are incorporated by reference. Examples Example 1 N42-fluoro-5-(trifluoromethyl)phenyl]-N'-{4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-l,3- thiazol-5-yl]phenyl}urea Example 1A l-(2-fluoro-5-(trifluoromethyl)phenyl)-3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenyl)urea To an ambient solution of 4-(4,4,5,5-tetramemyl-l,3,2-dioxaborolan-2-yl)aniline (2.0 g, 9.13 mmol) in tetrahydrofuran (30 mL) was added 2-fluoro-5-trifluoromethylphenyl isocyanate (1.32 mL, 9.13 mmol). After 1 h, the mixture was concentrated under reduced pressure to afford the title compound as a white solid. MS (ESI) m/z 425 [M+H]+. Example IB 4-(5-iodothiazol-2-yl)tetrahydro-2H-pyran-4-ol To a cold (-78 °C) solution of thiazole (2.0 mL, 28.2 mmol) in tetrahydrofuran (140 mL) was added n- butyllithium (11.4 mL, 28.2 mmol, 2.48 M in hexane) dropwise. After 15 minutes, dihydro-2#-pyran-4(3#)-one (2.59 mL, 28.2 mmol) was added in a single portion. After 30 minutes, w-butyllithium (11.4 mL, 28.2 mmol, 2.48 M in hexane) was added dropwise. The reaction was allowed to stir for an additional 20 minutes, after which a solution of iodine (7.24 g, 28.2 mmol) in tetrahydrofuran (15 mL) was added dropwise. The reaction was then quenched by the addition of saturated aqueous Na2S2O3 and ethyl acetate (100 mL) and allowed to warm to ambient temperature. The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 100 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated to give a dark solid. Trituration of the residue with dichloromethane gave the title compound as a beije solid. MS (ESI)m/z312[M+H]+. Example 1C N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-l,3- thiazol-5-yl]phenyl}urea A solution of Example IB (183 mg, 0.59 mmol), Example 1A (250 mg, 0.59 mmol), CsF (269 mg, 1.77 mmol), and tetrakis(triphenylphosphme)palladium(O) (69 mg, 0.06 mmol) in a solvent mixture of dimethoxyethane (1 mL) and methanol (1 mL) was heated to 90 °C for 16 h. The reaction was cooled to ambient temperature and diluted with ethyl acetate (2 mL) and H20 (1 mL). The layers were separated, and the organic was dried with anhydrous Na2SO4, filtered, and concentrated to give a solid. The residue was purified via RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min.) to provide the title compound as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.69 (br d, J= 12.2 Hz, 2 H), 2.07-2.17 (m, 2 H), 3.70-3.76 (m, 4 H), 6.16 (s, 1 H), 7.37-7.42 (m, 1 H), 7.51-7.54 (m, 3 H), 7.59 (m, 2 H), 8.00 (s, 1 H), 8.61 (m, 1 H), 8.94 (m, 1 H), 9.35 (s, 1 H); MS (ESI) m/z 482 [M+H]+. Example 2 N-{4-[2-(l-ethyl-4-hydroxypiperidin-4-yl)-1,3-thiazol-5-yl]phenyl}-N'-[2-fluoro-5- (trifluoromethyl)phenyl]urea Example 2A l-ethyl-4-(5-iodothiazol-2-yl)piperidin-4-ol Example 2A was prepared according to the procedure described for Example 1A, substituting l-ethylpiperidin-4-one for dihydro-2#-pyran-4(3/f)-one. MS (ESI) m/z 338 [M+H]+. Example 2B N-{4-[2-(l-ethyl-4-hydroxypiperidin-4-yl)-l,3-thiazol-5-yl]phenyl}-N'-[2-fluoro-5- (trifluoromethyl)phenyl]urea The trifluoroacetic acid salt of the title compound was prepared according to the procedure described for Example 1C, substituting Example 2A for Example IB. 1H NMR (300 MHz, DMSO-d6) 6 ppm 1.06 (t, J= 7.1 Hz, 3 H), 1.78 (br d, J= 11.5 Hz, 2 H), 2.12 (br t, /= 10.9 Hz, 2 H), 2.69-2.87 (m, 2 H), 3.30-3.44 (m, 4 H), 6.00 (s, 1 H), 7.38-7.43 (m, 1 H), 7.48-7.54 (m, 3 H), 7.58 (m, 2 H), 7.99 (s, 1 H), 8.61 (m, 1 H), 8.93 (m, 1 H), 9.32 (s, 1 H); MS (ESI) m/z 509 [M+H]+. Example 3 4-(5-{4-[(5,7-dimethyl-l,3-benzoxazol-2-yl)amino]-3-fluorophenyl}-l,3-thiazol-2- yl)tetrahydro-2H-pyran-4-ol Example 3A AT-(4-bromo-2-fluorophenyl)-5,7-dimethylbenzo[d]oxazol-2-amine An ambient solution of 2-amino-4,6-dimethylphenol (0.85 g, 6.2 mmol) and 2-fluoro-4-bromophenyl isothiocyanate (1.44 g, 6.20 mmol) in tetrahydrofuran (20 mL) was stirred for 16 h. The reaction was cooled (0 °C), and LiOH»H20 (0.521 g, 12.41 mmol) was added, followed by the dropwise addition of 30% H2O2 (3.41 mL, 31.0 mmol) over 15 minutes. The reaction was warmed to room temperature and stirred for 16h. The reaction was then quenched by the addition of 20% aqueous sodium sulfite solution (50 mL) and ethyl acetate (75 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 75 mL). The combined organics were dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by chromatography on Si02 gel, eluting with 25% ethyl acetate in hexane, to give the title compound. MS (ESI) m/z 335 [M+H]+. Example 3B A'-(2-fiuoro-4-(4,4,5,5-tetramethyl-l,3i2-dioxaborolan-2-yl)phenyl)-5,7-dimethylbenzo[d]oxazol-2-amine A mixture of Example 3A (2.34 g, 6.98 mmol), 4,4,4',4,,5,5,5')5,-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (2.13 g, 8.38 mmol), potassium acetate (2.06 g, 21.0 mmol) and [l,r-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with CH2CI2 (0.171 g, 0.209 mmol) in dioxane (30 mL) was heated to 95 °C for 24 h. The reaction was cooled to room temperature and diluted with brine (100 mL) and ethyl acetate (100 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 75 mL). The combined organics were dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by chromatography on SiO2 gel, eluting with 25% ethyl acetate in hexane, to give the title compound. MS (ESI) m/z 383 [M+H]+. Example 3C 4-(5- {4-[(5,7-dimethyl-l ,3-benzoxazol-2-yl)amino]-3-fluorophenyl} -1,3-thiazol-2- yl)tetrahydro-2H-pyran-4-ol A solution of Example 3B (0.062 g, 0.161 mmol), Example IB (0.050 g, 0.161 mmol), CsF (0.073 g, 0.482 mmol), and tetrakis(triphenylphosphine)palladium(O) (0.019 g, 0.0161 mmol) in a solvent mixture of dimethoxyethane/methanol (1/1,1 mL) was heated to 90 °C for 16 h. The reaction was cooled to room temperature and partitioned between H20 (2 mL) and ethyl acetate (2 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2x2 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-CIS 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min.) to provide the title compound as a white solid. XH NMR (300 MHz, DMSO-dg) δ ppm 1.69 (d, J= 12.6 Hz, 2 H), 2.08-2.20 (m, 2 H), 2.34 (s, 3 H), 2.39 (s, 3 H), 3.64-3.87 (m, 4 H), 6.20 (s, 1 H), 6.80 (s, 1 H), 7.08 (s, 1 H), 7.51 (m, 1 H), 7.65 (m, 1 H), 8.10 (s, 1 H), 8.34 (m, 1 H), 10.50 (s, 1 H); MS (ESI) m/z 440[M+H]+. Example 4 4-(5-{4-[(7-memyl-l,3-benzoxazol-2-yl)amino]phenyl}-l,3-thiazol-2-yl)tetrahydro- 2H-pyran-4-ol Example 4A N-(4-bromophenyl)-7-methylbenzo[d]oxazol-2-amine An ambient solution of 2-amino-6-methylphenol (0.74 g, 6.0 mmol) and 4-bromophenyl isothiocyanate (1.28 g, 6.0 mmol) in tetrahydrofuran (20 mL) was stirred for 16 h. The reaction was cooled (0 °C), and LiOH»H20 (0.521 g, 12.41 mmol) was added, followed by the dropwise addition of 30% H202 (3.41 mL, 31.0 mmol) over 15 minutes. The reaction was warmed to room temperature and stirred for 16h. The reaction was then quenched by the addition of 20% aqueous sodium sulfite solution (50 mL) and ethyl acetate (75 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 75 mL). The combined organics were dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by chromatography on SiO2 gel, eluting with 25% ethyl acetate in hexane, to give the title compound. MS (ESI) m/z 303 [M+H]+. Example 4B 7-me%l-A^<4-(4,4,5,5-tetramemyl-l,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazol-2-arnine Example 4B was prepared according to the procedure described for Example 3B, substituting Example 4A for Example 3A. MS (ESI) m/z 351 [M+H]+. Example 4C 4-(5-{4-[(7-methyl-l,3-benzoxazol-2-yl)amino]phenyl}-l,3-thiazol-2-yl)tetrahydro- 2H-pyran-4-ol Example 4C was prepared according to the procedure described for Example 3C, substituting Example 4C for Example 3B. 'H NMR (300 MHz, DMSO-d6) δ ppm 1.69 (d, J = 12.2 Hz, 2 H), 2.04-2.20 (m, 2 H), 2.44 (s, 3 H), 3.66-3.81 (m, 4 H), 6.14 (s, 1 H), 6.98 (m, 1 H), 7.13 (m, 1 H), 7.30 (m, 1 H), 7.60-7.71 (m, 2 H), 7.76-7.87 (m, 2 H), 7.99 (s, 1 H), 10.83 (s, 1 H); MS (ESI) m/z 408 [M+H]+. Example 5 4-(5- {2-chloro-4-[(7-chloro-1,3-benzoxazol-2-yl)amino]phenyl} -1,3-thiazolT2-yl)tetrahydro- 2H-pyran-4-ol Example 5A N-(4-bromo-3-chlorophenyl)-7-chlorobenzo[d]oxazol-2-amine An ambient solution of 2-amino-6-chlorophenol (0.86 g, 6.0 mmol) and 3-chloro-4-bromophenyl isothiocyanate (1.49 g, 6.0 mmol) in tetrahydrofuran (20 mL) was stirred for 16 h. The reaction was cooled (0 °C), and LiOH»H20 (0.521 g, 12.41 mmol) was added, followed by the dropwise addition of 30% H202 (3.41 mL, 31.0 mmol) over 15 minutes. The reaction was wanned to room temperature and stirred for 16h. The reaction was then quenched by the addition of 20% aqueous sodium sulfite solution (50 mL) and ethyl acetate (75 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 75 mL). The combined organics were dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by chromatography on S1O2 gel, eluting with 25% ethyl acetate in hexane, to give the title compound. MS (ESI) m/z 359 [M+H]+. Example 5B 7-chloro-N-(3-chloro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazol- 2-amine Example 5B was prepared according to the procedure described for compound 3B, substituting Example 5A for Example 3A. MS (ESI) m/z 405 [M+H]+. Example 5C 4-(5- {2-chloro-4-[(7-chloro-1,3-benzoxazol-2-yl)amino]phenyl} -1,3-thiazol-2-yl)tetrahydro- 2H-pyran-4-ol Example 5C was prepared according to the procedure described for Example 3G, substituting Example 5B for Example 3B. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.70 (d, J = 12.2 Hz, 2 H), 2.04-2.21 (m, 2 H), 3.65-3.84 (m, 4 H), 6.23 (s, 1 H), 7.24-7.29 (m, 2 H), 7.51 (m, 1 H), 7.67-7.72 (m, 2 H), 7.95 (s, 1 H), 8.09 (s, 1 H), 11.36 (s, 1 H); MS (ESI) m/z 462 [M+H]+. Example 6 4-(5- {4-[(7-chloro-1,3-benzoxazol-2-yl)amino]-2-methylphenyl} -1,3-tbiazol-2-yl)tetrahydro- 2H-pyran-4-ol Example 6A N-(4-bromo-3-methylphenyl)-7-chlorobenzo[d]oxazol-2-amine Example 6A was prepared according to the procedure described for Example 5A, substituting 3-methyl-4-bromophenyl isothiocyanate for 3-chloro-4-bromophenyl isothiocyanate. MS (ESI) m/z 339 [M+H]+. Example 6B 7-chloro-N-(3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenyl)benzo[d]oxazol-2-amine Example 6B was prepared according to the procedure described for Example 3B, substituting Example 6A for Example 3A. MS (ESI) m/z 385 [M+H]+. Example 6C 4-(5- {4-[(7-chloro-1,3-benzoxazol-2-yl)amino]-2-methylphenyl} -1,3-thiazol-2-yl)tetrahydro- 2H-pyran-4-ol Example 6C was prepared according to the procedure described for Example 3C, substituting Example 6B for Example 3B. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.71 (d, J = 12.2 Hz, 2 H), 2.06-2.22 (m, 2 H), 2.40 (s, 3 H), 3.65-3.84 (m, 4 H), 6.17 (s, 1 H), 7.16-7.33 (m, 2 H), 7.37-7.53 (m, 2 H), 7.62-7.76 (m, 3 H), 11.09 (s, 1 H); MS (ESI) m/z 519 [M+H]+. Example 7 N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{6-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-1,3- thiazol-5-yl]pyridin-3-yl}urea Example 7A 4-(5-(5-nitropyridin-2-yl)thiazol-2-yl)tetrahydro-2H-pyran-4-ol To a cold (-78 °C) solution of thiazole (0.382 mL, 5.41 mmol) in tetrahydrofuran (30 mL) was added n-butyllithium (3.38 mL, 5.41 mmol, 1.6 M in hexane) dropwise. After 15 minutes, dihydro-2H-pyran-4(3H)-one (0.49 mL, 5.41 mmol) was added in a single portion. After 30 minutes, n-buryllithium (3.38 mL, 5.41 mmol, 1.6 M in hexane) was added dropwise. The reaction was allowed to stir for an additional 20 minutes, after which ZnCl2 (10.8 mL, 10.8 mmol, 1 M in diethyl ether) was added. The cooling bath was removed, and the reaction warmed to room temperature. 2-Bromo-5-nitropyridine (1.10 g, 5.41 mmol) and tetrakis(triphenylphosphine)palladium(O) (0.623 g, 0.54 mmol) were added, and the reaction heated to 55 °C for 16 h. The reaction was cooled to ambient temperature and quenched by the addition of saturated NH4C1 (30 mL) and ethyl acetate (30 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 30 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on SiO2, eluting with a gradient of 10% ethyl acetate in hexane to 35% ethyl acetate in hexane, to give the title product. MS (ESI) m/z 308 [M+H]+. Example 7B 4-(5-(5-aminopyridin-2-yl)thiazol-2-yl)tetrahydro-2H-pyran-4-ol To a solution of Example 7 A (0.106 g, 0.344 mmol) in a solvent mixture of methanol (2 mL) and acetic acid (2 mL) was added Zn powder (0.067 g, 1.03 mmol). The reaction was heated to 50 °C for 5 h, and was then cooled to room temperature. The reaction was quenched by the addition of saturated aqueous NaHCO3 (5 mL) and ethyl acetate (5 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2x5 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure to yield the title compound, which was used without further purification. MS (ESI) m/z 278 [M+H]+. Example 7C N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'- {6-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-1,3- thiazol-5 -yl]pyridin-3-yl} urea To a solution of Example 7B (0.042 mg, 0.151 mmol) in tetrahydrofuran (1 mL) was added 2-fluoro-5-trifluoromethylphenyl isocyanate (0.022 mL, 0.151 mmol). After 1 h, the mixture was concentrated under reduced pressure. The residue was purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to provide the title compound as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.68 (br d, J= 12.9 Hz, 2 H), 2.07-2.17 (m, 2 H), 3.68-3.80 (m 4 H), 6.15 (s, 1 H), 7.40-7.45 (m, 1 H), 7.52 (m, 1 H), 7.89 (m, 1 H), 8.08 (m, 1 H), 8.25 (s, 1 H), 8.55-8.60 (m, 2 H), 9.10 (s, 1 H), 9.40 (s, 1 H); MS (ESI) m/z 483[M+H]+. Example 8 N-{4-[2-(l-ethyl-4-hydroxypiperidin-4-yl)-l,3-thiazol-5-yl]-2-fluorophenyl}-N-[2-fluoro-5- (trifluoromethyl)phenyl]urea Example 8A tert-butyl 4-(2-( 1 -ethyl-4-hydroxypiperidin-4-yl)thiazol-5 -yl)-2-fluorophenylcarbamate A solution of Example 2A (0.33 g, 0.98 mmol), 4-(te^butoxycarbonylamino)-3-fluorophenylboronic acid (0.25 g, 0.98 mmol), CsF (0.46 g, 3.0 mmol), and tetrakis(triphenylphosphine)palladium(O) (0.12 g, 0.098 mmol) in a solvent mixture of dimethoxyethane (2 mL) and methanol (1 mL) was heated to 90 °C for 16 h. The reaction was cooled to ambient temperature and diluted with ethyl acetate (5 mL) and H2O (5 mL). The layers were separated, and the organic was washed with 10% aqueous HC1 (3x15 mL). 2N NaOH was added to the combined acidic aqueous layers until pH =8. The aqueous layer was extracted with ethyl acetate (3x15 mL). The extracts were then dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the title product as a solid. MS (ESI) m/z 422 [M+H]+. Example 8B 4-(5-(4-amino-3-fluorophenyl)thiazol-2-yl)-l-ethylpiperidin-4-ol To an ambient solution of Example 8 A (0.20 g, 0.48 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (2 mL). The reaction was stirred for 2 h, and was then concentrated under reduced pressure. The residue was partitioned between saturated aqueous NaHC03 (5 mL) and ethyl acetate (5 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2x5 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure to yield the title compound, which was used without further purification. MS (ESI) m/z 322 [M+H]+. Example 8C N- {4-[2-(l -ethyl-4-hydroxypiperidin-4-yl)-l ,3-thiazol-5-yl]-2-fluorophenyl} -A"-[2-fluoro-5- (trifluoromethyl)phenyl]urea To an ambient solution of Example 8B (0.02g, 0.062 mmol) in tetrahydrofuran (1 mL) was added 2-fluoro-5-trifluoromethylphenylisocyanate (0.010 g, 0.065 mmol). After 1 h, the mixture was concentrated under reduced pressure. The residue was purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min). The fractions containing the desired product were diluted with saturated aqueous NaHC(>3 and extracted with ethyl acetate. The organic layer was dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the title compound as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.01 (t, J= 7.1 Hz, 3 H), 1.73 (br d, J= 11.9 Hz, 2 H), 2.08 (dt,7= 11.9 and3.7 Hz, 2 H), 2.25-2.37 (m, 4 H), 2.64-2.73 (m, 2 H), 6.15 (s, 1 H), 7.33-7.52 (m, 3 H), 7.61 (m, 1 H), 8.05 (s, 1 H), 8.24 (m, 1 H), 8.64 (m, 1 H), 8.90 (s, 1 H), 9.34 (s, 1 H); MS (ESI) m/z 527 [M+H]+. Example 9 N-(2,5-difluorophenyl)-N'- {4-[2-( 1 -ethyl-4-hydroxypiperidin-4-yl)-1,3-thiazol-5-yl]-2- fiuorophenyljurea The title compound was prepared according to the procedure described for Example 8C, substituting 2,5-difluorophenylisocyanate for 2-fluoro-5- trifluoromethylphenylisocyanate. 'HNMR (300 MHz, DMSO-d6) δ ppm 1.03 (t, J= 7.1 Hz, 3 H), 1.73 (br d, J= 11.9 Hz, 2H), 2.08 (dt,J= 11.9 and 3.7 Hz, 2 H), 2.33-2.44 (m, 4 H), 2.71-2.76 (m, 2 H), 6.85 (s, 1 H), 7.21-7.29 (m, 1 H), 7.36-7.44 (m, 2 H), 7.63-7.69 (m, 1 H), 8.02-8.07 (m, 1 H), 8.10 (s, 1 H), 8.22 (m, 1 H), 8.90 (s, 1 H), 9.30 (s, 1 H); MS (ESI) m/z 477[M+H]+. Example 10 N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{6-[2-(l-hydroxycyclopentyl)-l,3-thiazol-5- yl]pyridin-3-yl} urea Example 10A l-(5-Iodo-tbiazol-2-yl)-cyclopentanol Example 10A was prepared according to the procedure described for Example IB, substituting cyclopentanone for dihydro-2#-pyran-4(3#)-one., MS (ESI) m/z 296 [M+H]+. Example 10B l-(5-(5-nitropyridin-2-yl)thiazol-2-yl)cyclopentanol Example 10B was prepared according to the procedure described for Example 7A, substituting cyclopentanone for dihydro-2.ff-pyran-4(3i/)-one. MS (ESI) m/z 292 [M+H]+. Example IPC l-(5-(5-aminopyridin-2-yl)thiazol-2-yl)cyclopentanol Example 10C was prepared according to the procedure described for Example 7B, substituting Example 10B for Example 7A. MS (ESI) m/z 262 [M+H]+. Example 10P N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{6-[2-(l-hydroxycyclopentyl)-l,3-thiazol-5- yl]pyridin-3 -yl} urea Example 10D was prepared according to the procedure described for Example 7C, substituting Example IOC for Example 7B. lH NMR (300 MHz, DMSO-d6) δ ppm 1.74-1.92 (m, 6 H), 2.04-2.12 (m, 2 H), 6.50 (s, 1 H), 7.40-7.42 (m, 1 H), 7.4 (m, 1 H), 7.87 (m, 1 H), 8.07 (m, 1 H), 8.21 (s, 1 H), 8.56-8.58 (m, 2 H), 8.93 (s, 1 H), 9.44 (s, 1 H); MS (ESI) m/z 467 [M+H]+. Example 11 phenyl 4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-1,3-thiazol-5-yl]phenylcarbamate Example 11A 4-(5-(4-nitrophenyl)thiazol-2-yl)tetrahydro-2H-pyran-4-ol A solution of Example 1B (1.0 g, 3.2 mmol), 4-nitrophenylboronic acid (0.75 g, 4.5 mmol), KF (0.56 g, 9.6 mmol), and bis(triphenylphosphine)palladium(II) dichloride (0.22 g, 0.32 mmol) in a solvent mixture of dimethoxyethane (5 mL) and methanol (5 mL) was heated to 90 °C for 16 h. The reaction was cooled to room temperature and partitioned between ethyl acetate (10 mL) and H2O (10 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 10 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on Si02 gel, eluting with 50% ethyl acetate in hexane, to give the title compound. MS (ESI) m/z 307 [M+H]+. Example 11B 4-(5-(4-aminophenyl)thiazol-2-yl)tetrahydro-2H-pyran-4-ol Example 11B was prepared according to the procedure described for 7B, substituting Example 11A for Example 7A. MS (ESI) m/z 277 [M+H]+. Example 11C phenyl 4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-l,3-thiazol-5-yl]phenylcarbamate To an ambient solution of Example 11B (0.040 g, 0.145 mmol) and triethylamine (0.020 mL, 0.145 mmol)in tetrahydrofuran (1 mL) was added phenylchloroformate (0.016 mL, 0.145 mmol). After 16 h, the reaction was concentrated under reduced pressure. The residue was purified by chromatography on SiCh gel, eluting with ethyl acetate, to yield the title compound. 1H NMR (300 MHz, DMSO-dg) δ ppm 1.57-1.77 (m, 2 H), 2.02-2.20 (m, 2 H), 3.64-3.81 (m, 4 H), 6.12-6.18 (m, 1 H), 7.12-7.19 (m, 1 H), 7.22-7.28 (m, 2 H), 7.40-7.48 (m, 2 H), 7.54-7.65 (m, 4 H), 8.00 (s, 1 H); MS (ESI) m/z 397 [M+H]+. Example 12 N-{4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-l,3-thiazol-5-yl]phenyl}piperidine-l- carboxamide To an ambient solution of Example 1 IB (0.040 g, 0.145 mmol) and triethylamine (0.020 mL, 0.145 mmol)in tetrahydrofuran (1 mL) was added piperidine-1-carbonyl chloride (0.018 mL, 0.145 mmol). After 16 h, the reaction was concentrated under reduced pressure. The residue was purified by chromatography on SiCh gel, eluting with ethyl acetate, to yield the title compound. 1H NMR (300 MHz, DMSO-ds) δ ppm 1.43-1.62 (m, 6 H), 1.68 (d, J= 12.2 Hz, 2 H), 2.02-2.21 (m, 2 H), 3.39-3.46 (m, 4 H), 3.64-3.80 (m, 4 H), 6.12 (s, 1 H), 7.45-7.56 (m, 4 H), 7.94 (s, 1 H), 8.56 (s, 1 H); MS (ESI) m/z 388 [M+H]+. Example 13 fe^-butyl3-(5-{4-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyl}- 1,3-thiazol-2-yl)-3-hydroxypyrrolidine-l -carboxylate Example 13A ter/-butyl 3-hydroxy-3-(5-iodothiazol-2-yl)pyrrolidine-1 -carboxylate To a cold (-78 °C) solution of thiazole (0.382 mL, 5.41 mmol) in tetrahydrofuran (30 mL) was added M-butyllithium (3.38 mL, 5.41 mmol, 1.6 M in hexane) dropwise. After 15 minutes, N-boc-3-pyrrolidinone (0.49 mL, 5.41 mmol) was added in a single portion. After 30 minutes, lithium diisopropylamide (5.41 mL, 5.41 mmol, 1.0 M in tetrahydrofuran) was added dropwise. The reaction was allowed to stir for an additional 30 minutes, after which a solution of h (137 g, 5.4 mmol) in tetrahydrofuran (10 mL) was added dropwise. After 10 minutes, the reaction was then quenched by the addition of saturated aqueous Na2S23 (100 mL) and ethyl acetate (100 mL) and allowed to warm to ambient temperature. The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 100 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated to give a dark solid. The residue was purified by chromatography on Si02 gel, eluting with 50% ethyl acetate in hexanes, to give the title product as a solid. MS (ESI) m/z 397 [M+H]+. Example 13B fert-butyl3-(5-{4-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyl}-l,3-thiazol-2-yl)-3-hydroxypyrrolidine-l-carboxylate Example 13B was prepared according to the procedure described for Example 1C, substituting Example 13A for Example IB. lH NMR (500 MHz, DMSO-aV) δ ppm 1.33-1.49 (m, 9 H), 2.05-2.17 (m, 1 H), 2.28-2.42 (m, 1 H), 3.40-3.53 (m, 1 H), 3.52-3.61 (m, 2 H), 3.62-3.71 (m, 1 H), 6.54 (s, 1 H), 7.34-7.65 (m, 6 H), 8.04 (s, 1 H), 8.56-8.66 (m, 1 H), 8.93 (m,l H), 9.28-9.40 (m,lH); MS (ESI) m/z 567 [M+H]+. Example 14 N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{4-[2-(3-hydroxypyrrolidui-3-yl)-l,3-thiazol-5- yl]phenyl}urea To an ambient solution of Example 13B (0.30 g, 0.53 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (2 mL). After 1 h, the solution was concentrated under reduced pressure. The residue was partitioned between saturated aqueous NaHCCh (5 mL) and ethyl acetate (5 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2x5 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure to yield the title compound. 1H NMR (500 MHz, DMSO-ds) δ ppm 1.97-2.11 (m, 1 H), 2.23-2.32 (m, 1 H), 2.91-3.08 (m, 2 H), 3.07-3.19 (m, 2 H), 4.06-4.17 (m, 1 H), 6.17 (s, 1 H), 7.35-7.70 (m, 6 H), 7.99 (s, 1 H), 8.56-8.67 (m, 1 H), 8.95 (s, 1 H), 9.37 (s, 1 H); MS (ESI) m/z 467 [M+H]+. Example 15 N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{4-[2-(3-hydroxy-l-methylpyrrolidin-3-yl)-l,3- thiazol-5-yl]phenyl}urea To an ambient solution of Example 14 (0.050 g, 0.107 mmol) in methanol containing 1% v/v acetic acid 1 mL) was added formaldehyde (0.012 mL, 0.161 mmol, 37 wt% in H20) and MP-CNBH3 (0.054 g, 0.161 mmol, 3.0 mmol/g). The reaction was heated to 50 °C and shaken for 16 h. The reaction was then filtered and concentrated under reduced pressure. The residue was purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min). The fractions containing the desired product were diluted with saturated aqueous NaHCO3 and extracted with ethyl acetate. The organic layer was dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the title compound as a white solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 2.01-2.13 (m, 1 H), 2.25-2.33 (m, 3 H), 2.35-2.46 (m, 1 H), 2.51-2.58 (m, 1 H), 2.73-2.94 (m, 3 H), 6.22-6.31 (m, 1 H), 7.37-7.44 (m, 1 H), 7.47-7.56 (m, 3 H), 7.56-7.62 (m, 2 H), 7.98 (s, 1 H), 8.62 (m, 1 H), 8.92 (m, 1 H), 9.32 (s, 1 H); MS (ESI) m/z 481 [M+H]+. Example 16 N- {4-[2-( 1 -ethyl-3-hydroxypyrrolidin-3-yl)-1,3-thiazol-5-yl]phenyl} -N'-[2-fluoro-5- (trifluoromethyl)phenyl]urea The title compound was prepared according to the procedure described for Example 15, substituting acetaldehyde for formaldehyde. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.03 (t,/= 7.29 Hz, 3 H), 2.00-2.12 (m, 1 H), 2.34-2.43 (m, 1 H), 2.53-2.63 (m, 1 H), 2.83-2.96 (m, 3 H), 4.09 (m, 2 H), 6.24 (s, 1 H), 7.33-7.70 (m, 6 H), 7.98 (s, 1 H), 8.61 (m, 1 H), 8.92 (m, 1 H), 9.32 (s, 1 H); MS (ESI) m/z 495 [M+H]+. Example 17 N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{4-[2-(l-hydroxycyclopentyl)-l,3-thiazol-5- yl]phenyl}urea Example 17 was prepared according to the procedure described for 1C, substituting Example 10A for Example 1B lH NMR (500 MHz, DMSO-d6) δ ppm 1.69-1.95 (m, 6 H), 2.01-2.16 (m, 2 H), 5.91 (s, 1 H), 7.36-7.43 (m, 1 H), 7.47-7.55 (m, 3 H), 7.55-7.61 (m, 2 H), 7.96 (s, 1 H), 8.62 (m, 1 H), 8.92 (m, 1 H), 9.32 (s, 1 H); MS (ESI) m/z 466 [M+H]+. Example 18 N- {4-[2-(l -hydroxycyclopentyl)-1,3-thiazol-5-yl]phenyl} -N'-[3-(trifluoromethyl)phenyl]urea Example 18A l-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-3-(3-trifluoromethyl-phenyl)- urea Example 18A was prepared according to the procedure described for 1 A, substituting 3-trifluoromethylphenyl isocyanate for 2-fluoro-5-trifluoromethylphenyl isocyanate. MS (ESI) m/z 407 [M+H]+. Example 18B N-{4-[2-(l-hydroxycyclopentyl)-l,3-tbiazol-5-yl]phenyl}-N'-[3-(trifluoromethyl)phenyl]urea Example 18B was prepared according to the procedure described for 1C, substituting Example 10A for Example IB, and substituting Example 18A for Example 1A. 1H NMR (500 MHz, DMSO-d6) δ ppm 1.70-1.96 (m, 6 H), 2.01-2.17 (m, 2 H), 5.80 (s, 1 H), 7.32 (m, 1 H), 7.46-7.65 (m, 6 H), 7.95 (s, 1 H), 8.02 (s, 1 H), 8.96 (s, 1 H), 9.05-9.16 (m, 1 H); MS (ESI)m/z448[M+H]+. Example 19 N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'- {4-[2-(l -hydroxycyclobutyl)-l ,3-thiazol-5- yl]phenyl}urea Example 19A l-(5-Iodo-thiazol-2-yl)cyclobutanol Example 19A was prepared according to the procedure described for Example IB, substituting cyclobutanone for dihydro-2#-pyran-4(3.ff)-one. MS (ESI) m/z 282 [M+H]+. Example 19B N-[2-fluoro-5-(trifluoromethyl)phenyl]-N,-{4-[2-(l-hydroxycyclobutyl)-l,3-thiazol-5- yl]phenyl}urea Example 19B was prepared according to the procedure described for 1C, substituting Example 19A for Example IB. JH NMR (500 MHz, DMSO-ds) δ ppm 1.77-1.99 (m, 2 H), 2.25-2.39 (m, 2 H), 2.51-2.59 (m, 2 H), 6.49 (s, 1 H), 7.36-7.44 (m, 1 H), 7.47-7.55 (m, 3 H), 7.56-7.62 (m, 2 H), 8.00 (s, 1 H), 8.62 (m, 1 H), 8.92 (m, 1 H), 9.32 (s, 1 H); MS (ESI) m/z 452[M+H]+. Example 20 N- {4-[2-( 1 -hydroxycyclobutyl)-1,3-thiazol-5-yl]phenyl} -N'-[3-(trifluoromethyl)phenyl]urea Example 20 was prepared according to the procedure described for 1C, substituting Example 19A for Example IB, and substituting Example 18A for Example 1A. lH NMR (500 MHz, DMSO-dg) δ ppm 1.78-1.97 (m, 2 H), 2.26-2.39 (m, 2 H), 2.50-2.58 (m, 2 H), 6.49 (s, 1 H), 7.32 (m, 1 H), 7.45-7.64 (m, 6 H), 7.95-8.07 (m, 2 H), 8.96 (s, 2 H), 9.08 (s, 2 H); MS (ESI) m/z 434 [M+H]+. Example 21 (±)-Cis-3-hydroxy-3-{4'-[({[3-(trifluoromethyl)plienyl]amino}carbonyl)amino]-l,r- biphenyl-4-yl} cyclopentanecarboxylic acid Example 21A (±)-Cis-(lS,3S)-3-(4-Bromo-phenyl)-3-hydroxy-cyclopentanecarboxylic acid To a cold (-78 °C) solution of 1,4-dibromobenzene (1.0 g, 4.23 mmol) was added n-butyllithium (1.69 mL, 4.23 mmol, 2.5 M in hexane). After 30 minutes, (±)-3-oxo-cyclopentanecarboxylic acid (0.271 g, 2.12 mmol) was added as a solution in tetrahydrofuran (20 mL). The reaction was stirred for 30 minutes and then quenched by the addition of saturated aqueous NH4C1 (50 mL) and ethyl acetate (50 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 50 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by chromatography on SiO2 gel, eluting with ethyl acetate, to give the title compound. MS (ESI) m/z 287 [M+H]+. Example 21B (±)-Cis-3-hydroxy-3- {4'-[({[3-(trifluoromethyl)phenyl]amino} carbonyl)amino]-l, 1 '-biphenyl-4-yl} cyclopentanecarboxylic acid A mixture of Example 21A (0.041 g, 0.154 mmol), Example 18A (0.050 g, 0.154 mmol), Na2C03 (0.049 g, 0.46 mmol), andtetrakis(triphenylphosphine)palladium(O) (0.017 g, 0.015 mmol) in a toluene/dimethoxyethane/ethanol/H20 (10:3:2:1, l mL) solvent mixture was heated to 90 °C for 16 h. The reaction was cooled to room temperature and partitioned between 10% HC1 (5 mL) and ethyl acetate (5 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2x5 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to provide the title compound as a white solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 1.86-2.03 (m, 3 H), 2.14-2.26 (m, 3 H), 2.92-3.05 (m, 1 H), 4.97 (s, 1 H), 7.32 (m, 1 H), 7.47-7.66 (m, 10 H), 8.03 (s, 1 H), 8.89 (s, 1 H), 9.07 (s, 1 H), 12.0 (s, 1 H); MS (ESI) m/z 484 [M+H]+. Example 22 N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{4-[2-(l-methoxycyclopentyl)-l,3-thiazol-5- yl]phenyl}urea Example 22A 5-Iodo-2-(l-methoxy-cyclopentyl)-thiazole To a suspension of NaH (0.176 g, 4.41 mmol, 60 wt% in mineral oil) in N,N-dimethylformarnide (10 mL) was added Example 10A (1.0 g, 3.39 mmol). After 0.5 h, iodomethane (0.317 mL, 5.09 mmol) was added, and the reaction was stirred for 16 h. The reaction was partitioned between H2O (10 mL) and ethyl acetate (10 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2x10 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by chromatography on SiO2 gel, eluting with 5% ethyl acetate in hexane, to give the title compound. MS (ESI) m/z 310 [M+H]+. Example 22B N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{4-[2-(l-methoxycyclopentyl)-l,3-thiazol-5- yl]phenyl}urea Example 22B was prepared according to the procedure described for Example 1C, substituting Example 22A for Example IB. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.68-1.81 (m, 4 H), 2.03-2.16 (m, 4 H), 3.11-3.15 (m, 3 H), 7.35-7.44 (m, 1 H), 7.46-7.64 (m, 5 H), 8.00 (s, 1 H), 8.61 (m, 1 H), 8.93 (m, 1 H), 9.36 (s, 1 H); MS (ESI) m/z 553 [M+H]+. Example 23 {[1 -(5- {4-[( {[2-fluoro-5-(trifluoromethyl)phenyl]amino} carbonyl)amino]phenyl} -1,3- thiazol-2-yl)cyclopentyl]oxy} acetic acid Example 23A [l-(5-Iodo-thiazol-2-yl)-cyclopentyloxy]acetic acid ethyl ester Example 23A was prepared according to the procedure described for Example 22A, substituting bromoethylacetate for iodomethane. MS (ESI) m/z 382 [M+H]+. Example 23B {[l-(5-{4-[({[2-fluoro-5-(trifluoromethyl)phenyl]ainmo}carbonyl)amino]phenyl}-l,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid A solution of Example 23A (0.187 g, 0.491 mmol), Example 1A (0.208 g mL, 0.491 mmol), CsF (0.223 g, 1.47 mmol), andtetrakis(triphenylphosphine)palladium(O) (0.057 g, 0.049 mmol) in a solvent mixture of dimethoxyethane (1 mL) and methanol (1 mL) was heated to 90 °C for 16 h. The reaction was cooled to room temperature and diluted with H20 (5 mL). The solid was filtered, washed with diethyl ether, and air-dried to give the intermediate ester. The ester was dissolved in methanol (15 mL) and 2N NaOH (2 mL) and stirred for 16 h. The methanol was removed under reduced pressure, and the aqueous was washed with diethyl ether (20 mL). The aqueous was acidified to pH 1 with 10% HC1. The solid was filtered, washed with CH3GN, and air-dried to give the title compound. • H NMR . (300 MHz, DMSO-d6) δ ppm 1.66-1.91 (m, 4 H), 2.07-2.17 (m, 4 H), 3.91 (s, 2 H), 7.34-7.66 (m, 6 H), 8.02 (s, 1 H), 8.61 (m, 1 H), 9.02 (m, 1 H), 9.54 (s, 1 H), 10.45 (s, 1 H); MS (ESI) m/z 524 [M+H]+. Example 24 {[l-(5-{4-[(bicyclo[4.2.0]octa-l,3,5-trien-7-ylcarbonyl)amino]phenyl}-l,3-thiazol-2- yl)cyclobutyl]oxy} acetic acid Example 24A Ethyl 2-(l-(5-iodothiazol-2-yl)cyclobutoxy)acetate To an ambient suspension of NaH (0.390 g, 9.75 mmol) in N,N-dimethylformamide (40 mL) was added Example 19A (2.74 g, 9.75 mmol) as a solution in N,N- dimethylformamide (10 mL). After 1 h, ethyl 2-bromoacetate (1.08 mL, 9.75 mmol) was added in a single portion. After 16 h, the reaction was quenched by the addition of H20 (50 mL) and ethyl acetate (50 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 50 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on Si02 gel, eluting with a gradient of hexane to 5% ethyl acetate in hexane, to give the title compound. MS (ESI) m/z 368 [M+H]+. Example 24B Methyl 2-(l-(5-(4-aminophenyl)thiazol-2-yl)cyclobutoxy)acetate A solution of Example 24A (0.750 g, 2/04 mmol), CsF (0.930 g, 6.12 mmol), 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)aniline (0.447 g, 2.04 mmol), and tetrakis(triphenylphosphine)palladium(O) (0.231 g, 0.200 mmol) in a solvent mixture of dimethoxyethane (5 mL) and methanol (5 mL) was heated to 90 °C for 16 h. The reaction was cooled to room temperature and partitioned between H20 (10 mL) and ethyl acetate (10 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2x10 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on Si02 gel, eluting with a gradient of 10% ethyl acetate in hexane to 50% ethyl acetate in hexane, to give the title compound. MS (ESI) m/z 319 [M+H]+. Example 24C {[l-(5-{4-[(bicyclo[4.2.0]octa-l,3,5-trienr7-ylcarbonyl)amino]phenyl}-l,3-thiazol-2- yl)cyclobutyl]oxy} acetic acid To a solution of Example 24B (0.150 g, 0.470 mmol), 1,2-dihydrocyclobutabenzene-1-carboxylic acid (0.070 g, 0.470 mmol), N-methylmorpholine (0,103 mL, 0.940 mmol), and 1-hydroxybenzotriazole hydrate (0.080 g, 0.940 mmol) in N,N-dimethylformamide (2 mL) was added l-ethyl-3-[3-(dimemylamino)propyl]-carbodiimide hydrochloride (0.115 g, 0.589 mmol). The solution was heated to 50 °C for 3 h, cooled to room temperature, and partitioned between H20 (2mL) and ethyl acetate (2 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2x2 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (5 mL) and 2 N NaOH (0.50 mL) was added. After 5 h, the methanol was removed under reduced pressure. The aqueous was acidified with 10% HC1 to pH 1. The solid was filtered and air-dried. Purification of the residue by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) provided the title compound as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.67-1.94 (m, 2 H), 2.39-2.47 (m, 4 H), 3.31-3.40 (m, 2 H), 3.93 (s, 2 H,) 4.44 (dd, J= 4.9 and 2.9 Hz, 1 H), 7.09-7.31 (m, 4 H), 7.56-7.68 (m, 2 H), 7.67-7.78 (m, 2 H), 8.07 (s, 1 H), 10.37 (s, 1 H); MS (ESI) m/z 435 [M+H]+. Example 25 ({l-[5-(4- {[(2-fluorophenyl)acetyl]amino}phenyl)-l ,3-thiazol-2-yl]cyclobutyl}oxy)acetic acid Example 25 was prepared according to the procedure described for Example 24C, substituting 2-(2-fluorophenyl)acetic acid for 1,2-dihydrocyclobutabenzene-l-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.67-1.96 (m, 2 H), 2.39-2.47 (m, 4 H), 3.75 (s, 2 H,) 3.92 (s, 2 H), 7.10-7.25 (m, 2 H), 7.26-7.45 (m, 2 H), 7.53-7.75 (m, 4 H), 8.06 (s, 1 H), 10.37 (s, 1 H), 12.64 (s, 1 H); MS (ESI) m/z 441 [M+H]+. Example 26 {[ 1 -(5- {4-[(anilinocarbonyl)amino]phenyl} -1,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid Example 26A 1 -phenyl-3 -(4-(4,4,5,5 -tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea Example 26A was prepared according to the procedure described for Example 1A, substituting phenyl isocyanate for 2-fluor-5-trifluoromethylphenyl isocyanate. MS (ESI) m/z 339[M+H]+. Example 26B {[ 1 -(5-{4-[(anilinocarbonyl)amino]phenyl}-1,3-thiazol-2-yl)cyclopentyl]oxy}acetic acid Example 26B was prepared according to the procedure described for Example 23B, substituting Example 26A for Example 1 A. 1H NMR (300 MHz, DMSO-ds) δ ppm 1.62-1.95 (m, 4 H), 2.01-2.20 (m, 4 H), 3.90 (s, 2 H), 6.98 (m, 1 H), 7.21-7.36 (m, 2 H), 7.40-7.63 (m, 6 H), 8.00 (s, 1 H), 8.73 (s, 1 H), 8.88 (s, 1 H), 12.59 (s, 1 H); MS (ESI) m/z 438 [M+H]+. Example 27 {[1 -(5-{4-[(anilinocarbonyl)amino]phenyl}-1,3-thiazol-2-yl)cyclobutyl]oxy)acetic acid A solution of Example 24A (0.304 g, 0.953 mmol), Example 26A (0.209 g, 0.953 mmol), CsF (0.434 g, 2.86 mmol), andtetrakis(triphenylphosphine)palladium(O) (0.110 g, 0.095 mmol) in a solvent mixture of dimethoxyethane (5 mL) and methanol (5 mL) was heated to 90 °C for 16 h. The reaction was cooled to room temperature and diluted with H20 (10 mL). The solid was filtered, washed with diethyl ether, and air-dried to give the intermediate ester. The ester was dissolved in methanol (50 mL) and 2N NaOH (2 mL) and stirred for 16 h. The methanol was removed under reduced pressure, and the aqueous was washed with diethyl ether (15 mL). The aqueous was acidified to pH 1 with 10% HC1. The solid was filtered, washed with CH3CN, and air-dried to give the title compound. 1H NMR (500 MHz, DMSO-ds) δ ppm 1.67-1.97 (m, 2 H), 2.35-2.52 (m, 4 H), 3.93 (s, 2 H), 6.91-7.01 (m, 1 H), 7.23-7.33 (m, 2 H), 7.41-7.50 (m, 2 H), 7.51-7.59 (m, 4 H), 8.04 (s, 1 H), 8.73 (s, 1 H), 8.82 (s, 1 H), 8.97 (s, 1 H); MS (ESI) m/z 424 [M+H]+. Example 28 {[l-(5-{6-[(anilinocarbonyl)amino]pyridin-3-yl}-l,3-thiazol-2-yl)cyclopentyl]oxy}acetic acid Example 28A l-phenyl-3-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl)urea To an ambient solution of 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.350 g, 1.59 mmol) in tetrahydrofuran (4 mL) was added phenyl isocyanate (0.174 mL, 1.59 mmol). The solution was stirred at room temperature for 1 h and was then concentrated under reduced pressure. The solid was washed with diethyl ether (2 mL) and air-dried to give the title compound. MS (ESI) m/z 221 [M+H]+. Example 28B {[l-(5-{6-[(anilinocarbonyl)amino]pyridin-3-yl}-l,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid Example 28B was prepared according to the procedure described for Example 23B, substituting Example 28A for Example 1 A. 'H NMR (300 MHz, DMSO-ds) δ ppm 1.60-1.96 (m, 4 H), 2.13 (t, J= 5.26 Hz, 4 H), 3.92 (s, 2 H), 7.03 (t, J = 7.3 Hz, 1 H), 7.26-7.37 (m, 2 H), 7.47-7.58 (m, 2 H), 7.66 (m, 1 H), 7.99-8.14 (m, 2 H), 8.60 (m, 1 H), 9.57 (s, 1 H), 10.14 (s, 1 H), 12.60 (s, 1 H); MS (ESI) m/z 439 [M+H]+. Example 29 {[l-(5-{6-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]pyridin-3-yl}-l,3-thiazol-2- yl)cyclopentyl]oxy} acetic acid Example 29A l-(5-(4)4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl)-3-(3-(trifluoromethyl)phenyl)urea Example 29A was prepared according to the procedure described for Example 28A, substituting 3-trifluoromethylphenyl isocyanate for phenyl isocyanate. MS (ESI) m/z 408 [M+H]+. Example 29B {[l-(5-{6-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)arnino]pyridin-3-yl}-l,3-thiazol-2- yl)cyclopentyl]oxy} acetic acid Example 29B was prepared according to the procedure described for Example 23B, substituting Example 29A for Example 1 A. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.63-1.95 (m, 4 H), 2.13 (t, J= 5.1 Hz, 4 H), 3.92 (s, 2 H), 7.38 (d, J= 7.8 Hz, 1 H), 7,56 (t, J= 7.9 Hz, 1 H), 7.61-7.75 (m, 2 H), 7.95-8.15 (m, 3 H), 8.63 (m, 1 H), 9.70 (s, 1 H), 10.52 (s, 1 H), 12.61 (s, 1H); MS (ESI) m/z 507 [M+H]+. Example 30 {[l-(4-{6-[(anilinocarbonyl)amino]pyridin-3-yl}phenyl)cyclopentyl]oxy}acetic acid Example 30A 1-(4-Bromophenyl)cyclopentanol To a cold (-78 °C) solution of 1,4-dibromobenzene (33 g, 139.8 mmol) in tetrahydrofuran (200 mL) was added n-butyllithium (59.0 mL, 146.8 mmol, 2.49 M in hexane) dropwise. The viscous solution was stirred at -78 °C for 45min, and cyclopentanone (13.6 mL, 153.8 mmol) was then added dropwise over 30 min. The resulting solution was stirred at -78 °C for 1 h and was then quenched by the addition of 0.5M HC1 (200 mL) and ethyl acetate (200 mL). The layers were separated, and the organics were washed with water (1 x 100 mL), brine (1 x 100 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on SiCh gel, etuting with 5% ethyl acetate in hexane to give the title compound. 1H NMR (300 MHz, DMSO-dg) δ ppm 1.71-1.76 (m, 2 H), 1.78-1.88 (m, 6 H), 4.85 (s, 1 H), 7.39-7.43 (m, 2 H), 7.44-7.49 (m, 2 H). Example 30B 2-(l -(4-Bromophenyl)cyclopentyloxy)acetic acid To an ambient suspension of NaH (332 mg, 8.30 mmol, 60 wgt % in mineral oil) in N,N-dimethylformamide (2 mL) was added dropwise a solution of Example 30A (1.0 g, 4.15 mmol) inN,N-dimethylformamide (lmL). After 30 min., bromoacetic acid (577 mg, 4.15 mmol) in N,N-dimethylformamide (13 mL) was added dropwise. The solution was stirred at room temperature for 16 h and then heated to 50 °C for 3 h. The reaction was cooled to room temperature and was quenched by the addition of water (10 mL). The solution was basicified to pH 10 by the addition of 2.5 M NaOH. The aqueous was extracted with ethyl acetate (2 x 10 mL), and the organics discarded. The aqueous was acidified to pH 1 with 6 M HC1, and then extracted with ethyl acetate (3x10 mL). The combined organics were washed with water (3 x 10 mL), brine (1 x 10 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound. 1H NMR (300 MHz, DMSO-aV) δ ppm 1.66-1.72 (m, 2 H), 1.74-1.85 (m, 4 H), 2.02-2.15 (m, 2 H), 3.56-3.60 (m, 2 H), 7.33-7.39 (m, 2 H), 7.49-7.56 (m, 2 H), 12.37 (s, 1 H). Example 30C methyl 2-(l -(4-bromophenyl)cyclopentyloxy)acetate To an ambient solution of Example 30B (200 mg, 0.668 mmol) in N,N-dimethylformamide (4 mL) was added iodomethane (0.208 mL, 3.34 mmol) and potassium carbonate (184 mg, 1.34 mmol). The mixture was stirred at room temperature for 40 h, and then diluted with water (10 mL) and ethyl acetate (20 mL). The layers were separated, and the organic was washed with water (3.x lOmL), brine (1 x lOmL), dried over sodium sulfate, and concentrated under reduced pressure to give the title compound. 1H NMR (300 MHz, DMSO-dg) δ ppm 1.67-1.72 (m, 2 H), 1.74-1.84 (m, 4 H), 2.10 (m, 2 H), 3.58 (s, 3 H), 3.67- 3.70 (m, 2 H), 7.34-7.40 (m, 2 H), 7.51-7.57 (m, 2 H). Example 30D {[1 -(4-{6-[(anilinocarbonyl)amino]pyridin-3-yl}phenyl)cyclopeQtyl]oxy}acetic acid A solution of Example 30C (0.040 g, 0.122 mmol), Example 28A (0.041 g, 0.122 mmol), CsF (0.056 g, 0.366 mmol), and tetrakis(triphenylphosphine)palladium(O) (0.014 g, 0.012 mmol) in dimethoxyethane (0.5 mL) and methanol (0.5 mL) was heated to 90 °C for 16 h. The reaction was diluted with H2O (5 mL) and diethyl ether (5 mL), and the solid filtered. To the solid dissolved in a mixture of tetrahydrofuran (2 mL) and methanol (1 mL) was added 2 N NaOH (0.8 mL). After stirring at room temperature for 16 h, the organics were removed under reduced pressure. The aqueous was extracted with diethyl ether (1x5 mL), and the organics discarded. The aqueous was acidified to pH 1 with 10% HC1, and the solid was filtered. Purification of the solid residue by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) provided the title compound as a white solid. lH NMR (500 MHz, DMSO-d6) δ ppm 1.60-1.78 (m, 2 H), 1.77-1.91 (m, 4 H), 2.02-2.19 (m, 2 H), 3.53 (s, 2 H), 7.02 (t, J = 7.3 Hz, 1 H), 7.31 (t, J= 7.9 Hz, 2 H), 7.48-7.59 (m, 4 H), 7.61-7.72 (m, 3 H), 8.07 (m, 1 H), 8.61 (m, 1 H), 9.67 (s, 1 H); MS (ESI) m/z 432 [M+H]+. Example 31 (±)-Cis-3-(4'- {[(2-fluorophenyl)acetyl]amino) -1, l'-biphenyl-4-yl)-3- hydroxycyclopentanecarboxylic acid Example 31A (±)-Cis-methyl 3-(4-bromophenyl)-3-hydroxycyclopentanecarboxylate To an ambient solution of Example 21A (1.69 g, 5.93 mmol) in methanol (15 mL) was added trimethylsilyldiazomethane (5.0 mL, 10.0 mmol, 2.0 M in tetrahydrofuran). The reaction was quenched by the addition of acetic acid (2 mL) and concentrated under reduced pressure. Purification of the residue by chromatography on Si02 gel, eluting with 25% ethyl acetate in hexane, gave the title product as an oil. MS (ESI) m/z 299 [M+H]+. Example 3 IB (±)-Cis-methyl3-(4'-aminobiphenyl-4-yl)-3-hydroxycyclopentanecarboxylate A solution of Example 31A (0.500 g, 1.67 mmol), 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)aniline (0.366 g, 1.67 mmol), CsF (0.761 g, 5.01 mmol), and tetrakis(triphenylphosphine)palladium(O) (0.192 g, 0.167 mmol) in dirnethoxyethane (4.0 mL) and methanol(4.0 mL) was heated to 90 °C for 16 h. The reaction was cooled to room temperature and partitioned between H20 (10 mL) and ethyl acetate (10 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (10 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by chromatography on Si02 gel, eluting with ethyl acetate, to give the title compound. MS (ESI) m/z 312 [M+H]+. Example 31C (±)-Cis-3-(4'-{[(2-fluorophenyl)aceryl]amino} -1,1'-biphenyl-4-yl)-3-hydroxycyclopentanecarboxylic acid To a solution of Example 3 IB (0.100 g, 0.321 mmol), 2-(2'-fluorophenyl)acetic acid (0.0490 g, 0.321 mmol), 1-hydroxybenzotriazole hydrate (0.0540 g, 0.402 mmol), and N-methylmorpholine (0.070 mL, 0.064 mmol) in N,N-dimethylformamide was added l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (0.0770 g, 0.402 mmol). The reaction was heated to 50 °C for 3 h, cooled to room temperature, and partitioned between H20 (5 mL) and ethyl acetate (5 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 5 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was dissolved in methanol (10 mL), and 2 N NaOH (1 mL) was added. The reaction was stirred at room temperature for 16 h. The methanol was removed under reduced pressure, and the aqueous was acidified to pH 1 with 10% HC1. The solid was filtered, air-dried, and purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to provide the title compound as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.86-2.03 (m, 3 H), 2.14-2.26 (m, 3 H), 2.92-3.05 (m, 1 H), 4.06 (s, 2 H), 6.27 (s, 1 H), 7.16-7.20 (m, 2 H), 7.31-7.35 (m, 1 H), 7.39-7.42 (m, 1 H), 7.52-7.56 (m, 2 H), 7.62-7.71 (m, 6 H), 10.32 (s, 1 H), 12.0 (s, 1 H); MS (ESI) m/z 434 [M+H]+, Example 32 [(1 - {5-[4-( {2-[(4-chlorophenyl)amino]-3,4-dioxocyclobut-1 -en-1 -yl} amino)phenyl]-1,3- thiazol-2-yl}cyclobutyl)oxy]acetic acid Example 32A 3-(4-chlorophenylamino)-4-ethoxycyclobut-3-ene-1,2-dione To a refluxing solution of 3,4-diethoxycyclobut-3-ene-l,2-dione (1.05 g, 6.14 mmol) in ethanol (25 mL) was added an ethanol (10 mL) solution of 4-chloroaniline (0.784 g, 6.14 mmol) by syringe pump over 2 h. The heating bath was removed, and the reaction stirred at room temperature for 16 h. The reaction was concentrated under reduced pressure and purified by chromatography on SiO2 gel, eluting with 50% ethyl acetate in hexane to give the title compound. MS (ESI) m/z 252 [M+H]+. Example 32B [(l-{5-[4-({2-[(4-chlorophenyl)amino]-3,4-dioxocyclobut-l-en-l-yl}amino)phenyl]-l,3- thiazol-2-yl} cycloburyl)oxy]acetic acid A solution of Example 32A (0.063 g, 0.198 mmol) and Example 24B (0.050 g, 0.198 mmol) was heated to 90 °C for 16 h. The reaction was cooled to room temperature, and 2 N NaOH (0.5 mL) was added. After 16 h, the ethanol was removed under reduced pressure, and the aqueous acidified to pH 1 by the addition of 10% HO. The solid was filtered, air-dried, and purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 rnL/min) to provide the title compound as a white solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 1.72-1.95 (m, 2 H), 2.40-2.49 (m, 4 H), 3.93 (s, 2 H,) 7.40-7.47 (m, 2 H), 7.48-7.53 (m, 2 H), 7.55 (m, 2 H), 7.68 (m, 2 H), 8.11 (s, 1 H), 10.12 (m, 2 H), 12.0 (s, 1 H); MS (ESI) m/z 510[M+H]+. Example 33 {[ l-(5- {4-[(anilinocarbonyl)amino]phenyl} -4-methyl-1,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid Example 33A l-(5-iodo-4-methylthiazol-2-yl)cyclopentanol To a cold (-78 °C) solution of 4-methylthiazole (2.0 mL, 20.2 mmol) in tetrahydrofuran (130 mL) was added n-butyllithium (8.10 mL, 20.2 mmol, 2.48 M in hexane) dropwise. After 15 minutes, cyclopentanone (1.79 mL, 20.2 mmol) was added in a single portion. After 30 minutes, w-butyllithium (8.10 mL, 20.2 mmol, 2.48 M in hexane) was added dropwise. The reaction was allowed to stir for an additional 20 minutes, after which a solution of iodine (5.13 g, 20.2 mmol) in tetrahydrofuran (15 mL) was added dropwise. The reaction was then quenched by the addition of saturated aqueous Na2S2O3 and ethyl acetate (100 mL) and allowed to warm to ambient temperature. The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 100 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated to give a dark solid. Trituration of the residue with hexane gave the title compound as a beige solid. MS (ESI) m/z310[M+H]V Example 33B ethyl 2-(l-(5-iodo-4-methylthiazol-2-yl)cyclopentyloxy)acetate To a suspension of NaH (0,808 g, 20.2 mmol, 60 wt% in mineral oil) in N,N-dimethylformamide (40 mL) was added Example 33A (6.24 g, 20.2 mmol). After 0.5 h; ethyl bromoacetate (2.23 mL, 20.2 mmol) was added, and the reaction was stirred for 16 h. The reaction was partitioned between H20 (50 mL) and ethyl acetate (50 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 50 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by chromatography on SiQ2 gel, eluting with 5% ethyl acetate in hexane, to give the title compound. MS (ESI) m/z 396 [M+H]+. Example 33C {[l-(5-{4-[(anilinocarbonyl)amino]phenyl}-4-methyl-l,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid A solution of Example 33B (0.090 g, 0.228 mmol), Example 26A (0.077 g, 0.228 mmol), CsF (0.104 g, 0.684 mmol), and tetrakis(triphenylphosphine)palladium(O) (0.027 g, 0.023 mmol) in a solvent mixture of dimethoxyethane (1 mL) and methanol (1 mL) was heated to 90 °C for 16 h. The reaction was cooled to warm temperature and diluted with H20 (2 mL). The solid was filtered, washed with diethyl ether, and air-dried to give the intermediate ester. The ester was dissolved in a mixture of methanol (8 mL) and 2N NaOH (1 mL) and stirred for 16 h. The methanol was removed under reduced pressure, and the aqueous was washed with diethyl ether (5 mL). The aqueous was acidified to pH 1 with 10% HC1. The resulting solid was filtered, washed with CH3CN, air-dried, and purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifiuoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to provide the title compound as a white solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 1.66-1.90 (m, 4 H), 2.03-2.16 (m, 4 H), 2.40 (s, 3 H), 3.92 (s, 2 H), 6.98 (t, J= 7.48 Hz, 1 H), 7.24-7.32 (m, 2 H), 7.40 (m, 2 H), 7.46 (m, 2 H), 7.55 (m, 2 H), 8.71 (s, 1 H), 8.85 (s, 1 H), 12.38-12.80 (s, 1 H); MS (ESI) m/z 452 [M+H]+.. Example 34 {[1 -(4-methyl-5- {4-[( {[3-(trifluoromethyl)phenyl]amino} carbonyl)amino]phenyl} -1,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid Example 34 was prepared according to the procedure described for Example 33C, substituting Example 18A for Example 26A. 1H NMR (500 MHz, DMSO-d6) δ ppm 1.69-1.88 (m, 4 H), 2.03-2.14 (m, 4 H), 2.36-2.43 (m, 3 H), 3.92 (s, 2 H), 7.29-7.35 (m, 1 H), 7.39-7.44 (m, 2 H), 7.50-7.55 (m, 2 H), 7.55-7,62 (m, 2 H), 8.02 (s, 1 H), 8.99 (s, 1 H), 9.11 (s, 1 H); MS (ESI) m/z 521 [M+H]+. Example 35 {[l-(5-{6-[(anilinocarbonyl)amino]pyridin-3-yl}-4-methyl-l,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid Example 35 was prepared according to the procedure described for Example 33C, substituting Example 28A for Example 26A. lH NMR (500 MHz, DMSO-d6) δ ppm 1.64-1.92 (m, 4 H), 2.11 (t, .7=5.34 Hz, 4 H), 2.41 (s, 3 H), 3.94 (s, 2 H), 6.91-7.11 (m, 1 H), 7.24-7.37 (m, 2 H), 7.46-7.57 (m, 2 H), 7.60-7.73 (m, 1 H), 7.81-7.93 (m, 1 H), 8.32-8.46 (m, 1 H), 9.56 (s, 1 H), 10.21 (s, 1 H) ; MS (ESI) m/z 453 [M+H]+. Example 36 {[l-(4-methyl-5-{6-[({[3-(trifluoromethyl)phenyl]ammo}carbonyl)amino]pyridin-3-yl}-l,3- thiazol-2-yl)cyclopentyl]oxy} acetic acid Example 36 was prepared according to the procedure described for Example 33C, substituting Example 29A for Example 26A. 1H NMR (500 MHz, DMSO-dg) δ ppm 1.67-1.91 (m, 4 H), 2.02-2.17 (m, 4 H), 2.33-2.46 (m, 3 H), 3.91-3.97 (m, 2 H), 7.36-7.40 (m, 1 H), 7.49-7.62 (m, 1 H), 7.61-7.75 (m, 2 H), 7.90-7.92 (m, 1 H), 8.09 (s, 1 H), 8.44 (s, 1 H), 9.70 (s, 1 H), 10.60 (s, 1 H); MS (ESI) m/z 521 [M+H]+. Example 37 {[l-(5-{6-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amino]pyridin-3-yl}-l,3- tbiazol-2-yl)cyclopentyl]oxy} acetic acid Example 37A l-(2-fluoro-5-(trifluoromethyl)phenyl)-3-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyridm-2-yl)urea Example 37A was prepared according to the procedure described for Example 28A, substituting 2-fluoro-5-trifluoromethylphenylisocyanate for phenylisocyanate. MS (ESI) m/z 426[M+H]+. Example 37B {[l-(5-{6-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amino]pyridin-3-yl}-l,3- tm'azol-2-yl)cyclopentyl]oxy} acetic acid Example 37B was prepared according to the procedure described for Example 33C, substituting Example 37A for Example 26A, and substituting Example 23A for Example 33B. 'HNMR(300 MHz, DMSO-ds) δ ppm 1.65-1.91 (m, 4 H), 2.06-2.19 (m, 4 H), 3.92 (s, 2 H), 7.43-7.49 (m, 1 H), 7.51-7.59 (m, 1 H), 7.59-7.68 (m, 1 H), 8.08 (m, 1 H), 8.15 (s, 1 H), 8.56-8.63 (m, 1 H), 8.63-8.70 (m, 1 H), 10.09 (s, 1 H), 10.75 (s, 1 H); MS (ESI) m/z 584 [M+H]+. Example 38 2-{[l-(5-{6-[({[3-(trifluoromemyl)phenyl]ammo}carbonyl)ammo]pyridin-3-yl}-l,3-thiazol- 2-yl)cyclopentyl]oxy} propanoic acid Example 38A ethyl 2-(l-(5-iodothiazol-2-yl)cyclopentyloxy)propanoate Example 38A was prepared according to the procedure described for Example 22A, substituting ethyl 2-bromopropanoate for iodomethane. MS (ESI) m/z 396 [M+H]+. Example 38B 2-{[ 1-(5-{6-[( {[3-(trifluoromemyl)phenyl]amino} carbonyl)armno]pyridin-3-yl}-1,3-thiazol- 2-yl)cyclopentyl]oxy} propanoic acid A solution of Example 38A (0.040 g, 0.101 mmol), Example 29A (0.041 g, 0.101 mmol), CsF (0.046 g, 0.304 mmol), and tetrakis(triphenylphosphine)palladium(O) (0.0120 g, 0.010 mmol) in a solvent mixture of dimethoxyethane (0.5 mL) and methanol (0.5 mL) was heated to 90 °C for 16 h. The reaction was cooled to room temperature and diluted with H2O (2 mL). The solid was filtered, washed with diethyl ether, and air-dried to give the intermediate ester. The ester was dissolved in methanol (2 mL) and 2N NaOH (0.3 mL) and stirred for 16 h. The methanol was removed under reduced pressure, and the aqueous was washed with diethyl ether (2 mL). The aqueous was acidified to pH 1 with 10% HC1. The solid was filtered, washed with CH3CN, air-dried and purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to provide the title compound as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.25 (d, 7=6.78 Hz, 3 H), 1.64-1.78 (m, 2 H), 1.80-1.92 (m, 2 H), 1.96-2.18 (m, 3 H), 2.21-2.32 (m, 1 H), 3.84-4.00 (m, 1 H), 7.32-7.42 (m, 1 H), 7.50-7.60 (m, 2 H), 7.64-7.72 (m, 2 H), 8.03-8.12 (m, 2 H), 8.12 (s, 1 H), 8.51-8.70 (m, 1 H), 9.70 (s, 1 H), 10.51 (s, 1 H); MS (ESI) m/z 521 [M+H]+. Example 39 2- {[ l-(5- {6-[(anilinocarbonyl)amino]pyridin-3-yl} -1,3-thiazol-2- yl)cyclopentyl]oxy} propanoic acid Example 39 was prepared according to the procedure described for Example 38B, substituting Example 28A for Example 29A. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.25 (d, J= 6.78 Hz, 3 H), 1.63-1.78 (m, 2 H), 1.80-1.92 (m, 2 H), 1.93-2.04 (m, 2 H), 2.04-2.18 (m, 2 H), 2.20-2.33 (m, 1 H), 3.90-3.95 (m, 1 H), 7.35-7.41 (m, 1 H), 7.54-7.58 (m, 2 H), 7.63-7.72 (m, 2 H), 8.05-8.11 (m, 2 H), 8.12 (s, 1 H), 8.59-8.66 (m, 1 H), 9.70 (s, 1 H); MS (ESI) m/z521[M+H]+. Example 40 {[l-(5-{4-[(7-methyl-l,3-benzoxazol-2-yl)amino]phenyl}-l,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid A solution of Example 4B (0.20 g, 0.57 mmol), Example 23A (0.19 g, 0.57 mmol), CsF (0.26 g, 1.71 mmol), and tetrakis(triphenylphosphine)palladium(O) (0.066 g, 0.057 mmol) in a solvent mixture of dimethoxyethane (1 mL) and methanol (1 mL) was heated to 90 °C for 16 h. The reaction was cooled to room temperature and diluted with H2O (5 mL). The solid was filtered, air-dried. The solid was dissolved in tetrahydrofuran (10 mL) and methanol (10 mL) and 2 N NaOH (2 mL) was added. After 16 h, the organics were removed under reduced pressure, and the aqueous was acidified to pH 1 with 10% HC1. The solid was filtered, air-dried, and purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to provide the title compound as a white solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 1.65-1.77 (m, 2 H), 1.76-1.89 (m, 2 H), 2.08-2.20 (m, 4 H), 2.44 (s, 3 H), 3.91 (s, 2 H), 6.85-7.02 (m, 1 H), 7.10-7.19 (m, 1 H), 7.22-7.36 (m, 1 H), 7.59-7.70-7.75 (m, 2 H), 7.77-7.88 (m, 2 H), 7.94-8.05 (m, 1 H), 10.87 (s, 1 H); MS (ESI) m/z 482 [M+H]+. Example 41 N-{4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-l,3-thiazol-5-yl]phenyl}-2-[3- (trifluoromethyl)phenyl]acetamide A solution of Example 11B (0.025 g, 0.091mmol), 2-(3-(trifluoromethyl)phenyl)acetic acid (0.019 g, 0.091 mmol), l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (0.019 g, 0.10 mmol), 1-hydroxybenzotriazole hydrate (0.013 g, 0.10 mmol),and N-methylmorpholine (0.050 mL, 0.46 mmol) in N,N-dimethylformamide (1 mL) was heated to 55 °C for 16 h. The reaction was cooled to room temperature and diluted with ethyl acetate (2 mL) and H2O (2 x 1 mL). The layers were separated, and the organic was washed with brine (1 x 1 mL), dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to provide the title compound as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.66-1.72 (m, 2 H), 2.09-2.13 (m, 2 H,) 3.67-3.78 (m, 5 H), 3.80 (s, 2 H), 7.57-7.71 (m, 8 H), 7.99 (s, 1 H), 10.36 (s, 1 H); MS (ESI) m/z 463 [M+H]+. Example 42 2-(2,4-difluorophenyl)-N- {4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-1,3-thiazol-5- yl]phenyl) acetamide Example 42 was prepared according to that described for Example 41, substituting 2-(2,4-difluorophenyl)acetic acid for 2-(3-(trifluoromethyl)phenyl)acetic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.66-1.70 (m, 2 H), 2.092.13 (m, 2 H), 3.72-3.76 (m, 7 H), 7.02-7.08 (m, 1 H) 7.20-7.24 (m, 1 H) 7.40-7.48 (m, 1 H), 7.54-7.67 (m, 4 H), 8.00 (s, 1 H), 10.34 (s, 1 H); MS (ESI) m/z 431 [M+H]+. Example 43 2-(2,5-difIuorophenyl)-N- (4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-1,3-thiazol-5- yljphenyl} acetamide Example 43 was prepared according to that described for Example 41, substituting 2-(2,5-difluorophenyl)acetic acid for 2-(3-(trifluoromethyl)phenyl)acetic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.66-1.70 (m, 2 H), 2.06-2.16 (m, 2 H), 3.74-3.78 (m, 7 H), 7.15-7.30 (m, 3 H), 7.57-7.67 (m, 4 H), 8.00 (s, 1 H), 10.36 (s, 1 H); MS (ESI) m/z 431 [M+H]+. Example 44 [(1 - {5-[4-(benzoylamino)phenyl]-1,3-thiazol-2-yl) cyclobutyl)oxy]acetic acid A N,N-dimethylformamide (1 mL) solution of Example 24B (0.025 g, 0.079 mmol), benzoic acid (0.011 g, 0.087 mmol), l-emyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (0.015 g, 0.079 mmol), 1-hydroxybenzotriazole hydrate (0.011 g, 0.079 mmol), andN-methylmorpholine (0.345 mL, 0.314 mmol) was heated to 55 °C for 16 h. The solution was cooled to room temperature and diluted with ethyl acetate (2 mL) and H2O (2 mL). The layers were separated, and the organic was washed with brine (1 x 1 mL), dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (2 mL) and 2.5M NaOH (0.95 mL, 0.237 mmol) was added. The reaction was stirred at room temperature for 16 h, concentrated under reduced pressure, and purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column withUV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to provide the title compound as a white solid. 1H NMR (300 MHz, METHANOL-d4) δ ppm 1.83-1.93 (m, 1 H), 1.95-2.05 (m, 1 H), 2.53-2.67 (m, 5 H), 3.99 (s, 2 H), 7.49-7.60 (m, 4 H), 7.63-7.67 (m, 2 H) 7.81 (m, 2 H), 7.92-7.94 (m, 2 H), 7.97 (s, 1 H); MS (ESI) m/z 409 [M+H]+. Example 45 ({1 -[5-(4- {[(3-fluorophenyl)acetyl]amino}phenyl)-1,3-thiazol-2-yl]cyclobutyl} oxy)acetie acid Example 45 was prepared according to that described for Example 44, substituting 2-(3-fluorophenyl)acetic acid for benzoic acid. 1H NMR (300 MHz, METHANOL-di) δ ppm 1.81-1.92 (m, 1 H), 1.93-2.05 (m, 1 H), 2.50-2.65 (m, 5 H), 3.71 (s, 2 H), 3.94-3.98 (m, 2 H), 7.00 (m, 1 H), 7.09-7.19 (m, 2 H), 7.34 (m, 1 H), 7.56-7.67 (m, 5 H), 7.93 (s, 1 H); MS (ESI) m/z 441 [M+H]+. Example 46 ({l-[5-(4-{[4-(trifluoromethyl)benzoyl]amino}phenyl)-l,3-thiazol-2- yl]cyclobutyl}oxy)acetic acid Example 46 was prepared according to that described for Example 44, substituting 4- (trifluoromethyl)benzoic acid for benzoic acid. 1H NMR (300 MHz, METHANOL-d4) δ ppm 1.88 (m, 1 H), 1.95-2.05 (m, 1 H), 2.51-2.66 (m, 5 H), 3.98 (s, 2 H), 7.66 (m, 2 H), 7.80-7.86 (m, 5 H), 7.98 (s, 1 H), 8.11 (m, 2 H); MS (ESI) m/z 477 [M+H]+. Example 47 [(l-{5-[4-({[2-fluoro-5-(trifluoromethyl)phenyl]acetyl}amino)phenyl]-l,3-thiazol-2- yl}cyclobutyl)oxy]acetic acid Example 47 was prepared according to that described for Example 44, substituting 2-(2-fluoro-5-(trifluoromethyl)phenyl)acetic acid for benzoic acid. 1H NMR (300 MHz, METHANOLS) δ ppm 1.87 (m, 1 H), 1.93-2.05 (m, 1 H), 2.49-2.64 (m, 5 H), 3.87 (s, 2 H), 3.97 (s, 2 H), 7.31 (m, 1 H), 7.57-7.68 (m, 6 H), 7.75 (m, 1 H), 7.94 (s, 1 H); MS (ESI) m/z 509 [M+H]+. Example 48 {[l-(5-{6-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]pyridin-3-yl}-l,3-oxazol-2- yl)cyclopentyl]oxy} acetic acid Example 48A 1-(oxazol-2-yl)cyclopentanol An ambient solution of oxazole (1.00 g, 14.5 mmol) and borane«tetrahydrofuran complex (14.5 mL, 14.5 mmol, 1 M in tetrahydrofuran) was stirred for 30 min. The reaction was cooled to -78 °C, and n-butyllithium (9.5 mL, 15.2 mmol, 1.6 M in hexane) was added dropwise. After 30 minutes, cyclopehtanone (1.42 mL, 16.0 mmol) was added dropwise. After 30 minutes, the cold (-78 °C) reaction was quenched by the addition of 5% acetic acid in ethanol (70 mL) and warmed to room temperature. The solution was diluted with diethyl ether (10 OmL) and saturated NaHCCh (50 mL). Layers were separated, and the organics were washed with brine (1x50 mL), dried over Na2SO4, concentrated under reduced pressure, and purified by chromatography on SiO2 gel, eluting with 50% ethyl acetate in hexane, to give the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.59-1.71 (m, 2 H), 1.72-1.84 (m, 2 H), 1.84-1.96 (m, 2 H), 1.98-2.09 (m, 2 H), 5.40 (s, 1 H), 7.11 (s, 1 H), 8.02 (s,lH). Example 48B l-(5-iodooxazol-2-yl)cyclopentanol To a cold (-78 °C) solution of Example 48A (500mg, 3.26mmol) in tetrahydrofuran (50 mL) was added n-butyllithium (4.08 mL, 6.53 mmol, 1.6M in hexane) dropwise. After stirring for 30 min, a solution of iodine (0.829 g;, 3.26 mmol) in tetrahydrofuran (5 mL) was added dropwise. After 2 h, the reaction was quenched by the addition of 10% Na2S203 solution (10 mL) and ethyl acetate (10 mL) and warmed to room temperature. The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 50 mL). The combined organics were washed with brine (1 x 50 mL), dried over Na2SO4, concentrated under reduced pressure, and purified by chromatography on SiCh gel, during with 50% ethyl acetate in hexane, to give the title compound. lE NMR (300 MHz, DMSO-d6) δ ppm 1.65 (s, 2 H), 1.79 (s, 2 H), 1.89 (s, 2 H), 2.02 (s, 2 H), 5.50 (s, 1 H), 7.22 (s, 1 H). Example 48C ethyl 2-( 1 -(5-iodooxazol-2-yl)cyclopentyloxy)acetate Example 48C was prepared according to the procedure described for 24A, substituting Example 48B for Example 19A. 1H NMR (300 MHz, DMSO-ds) δ ppm 1.14-1.17 (m, 3 H), 1.59-1.68 (m, 2 H), 1.71-1.81 (m, 2 H), 2.03-2.11 (m, 4 H), 3.92 (s, 2 H), 3.99-4.06 (m, 2 H), 7.28 (s, 1 H). Example 48D {[l-(5-{6-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]pyridin-3-yl}-l,3-oxazol-2- yl)cyclopentyl]oxy} acetic acid A solution of Example 48C (0.103 g, 0.282 mmol), Example 29A (0.115 g, 0.282 mmol), GsF (0.129 g, 0.847 mmol), and tetrakis(triphenylphpsphine)palladium(O) (0.033 g, 0.028 mmol) in dimethoxyethane (2 mL) and ethanol (1 mL) was heated under microwave irradiation to 150 °C for 5 min. The reaction was then concentrated under reduced pressure. The residue was purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to provide the intermediate ester. The ester was dissolved in methanol (2 mL) and 2.5M NaOH (0.340 mL) was added. After 16 h, the organics were removed under reduced pressure. The aqueous was acidified to pH 1 with 10% HC1. The solid was filtered, washed with CH3CN, and dried to give the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.67 (m, 2 H), 1.82 (m, 2 H), 2.12-2.22 (m, 4 H), 3.92 (s, 2 H), 7.38 (m, 1 H), 7.52-7.60 (m, 1 H), 7.61 (s, 1 H,) 7.69 (m, 2 H), 8.06-8.10 (m, 2 H), 8.69 (m, 1 H), 9.74 (s, 1 H), 10.52 (s, 1 H), 12.45 (s, 1 H); MS (ESI) m/z 491 [M+H]+. Example 49 ({1 -[5-(4- {[(2,5-difluorophenyl)acetyl]amino}phenyl)-1,3-thiazol-2-yl]cyclobutyl} oxy)acetic acid Example 49 was prepared according to the procedure described for Example 44, substituting 2-(2,5-difluorophenyl)acetic acid for benzoic acid. 1H NMR (300 MHz, DMSO-de) δ ppm 1.73-1.83 (m, 1 H), 1.83-1.94 (m, 1 H), 2.43-2.48 (m, 4 H), 3.75-3.79 (m, 2 H), 3.93 (s, 2 H), 7.15-7.31 (m, 3 H), 7.59-7.69 (m, 4 H), 8.07 (s, 1 H), 10.37 (s, 1 H), 12.66 (s, 1 H); MS (ESI) m/z 459 [M+H]+. Example 50 ({1 -[5-(4- {[(3,5-difluorophenyl)acetyl]amino}phenyl)-1,3-thiazol-2-yl]cycloburyl}oxy)acetic acid Example 50 was prepared according to the procedure described for Example 44, substituting 2-(3,5-difluorophenyl)acetic acid for benzoic acid. 1H NMR (300 MHz, DMSO-de) δ ppm 1.73-1.84 (m, 1 H), 1.84-1.93 (m, 1 H), 2.41-2.48 (m, 4 H), 3.73 (s, 2 H), 3.93 (s, 2 H), 7.03-7.17 (m, 3 H), 7.59-7.69 (m, 5 H), 8.06 (s, 1 H), 10.34 (s, 1 H); MS (ESI) m/z 459 [M+H]+. Example 51 ({l-[5-(4-{[(3,4-difluorophenyl)acetyl]amino}phenyl)-l,3-thiazol-2-yl]cyclobutyl}oxy)acetic acid Example 51 was prepared according to the procedure described for Example 44, substituting 2-(3,4-difluorophenyl)acetic acid for benzoic acid. 1H NMR (300 MHz, DMSO-de) δ ppm 1.73-1.83 (m, 1 H), 1.83-1.94 (m, 1 H), 2.41-2.48 (m, 4 H), 3.69 (s, 2 H), 3.93 (s, 2 H), 7.17 (m, 1 H), 7.34-7.43 (m, 2 H), 7.59-7.69 (m, 5 H), 8.06 (s, 1 H,) 10.32 (s, 1 H); MS (ESI) m/z 459 [M+H]+. Example 52 {[1 -(4- {6-[( {[3-(trifluoromethyl)phenyl]amino} carbonyl)amino]pyridin-3- yl}phenyl)cyclopentyl]oxy} acetic acid Example 52 was prepared according to the procedure described for Example 30D, substituting Example 29A for Example 28A. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.71 (s, 2 H), 1.79-1.91 (m, 4 H), 2.08-2.18 (m, 2 H), 3.63 (s, 2 H), 7.36-7.40 (m, 1 H), 7.50-7.55 (m, 2 H), 7.55-7.60 (m, 1 H,) 7.62-7.65 (m, 1 H), 7.67-7.71 (m, 3 H), 8.07-8.13 (m, 2 H), 8.64-8.68 (m, 1 H), 9.64 (s, 1 H), 10.72 (s, 1 H), 12.42 (s, 1 H); MS (ESI) m/z 500 [M+H]+. Example 53 2-(l-(2-fluoro-4-(6-(3-(3-(trifluoromethyl)phenyl)ureido)pyridin-3- yl)phenyl)cyclobutoxy)acetic acid Example 53A methyl 4-bromo-2-fluorobenzoate An ambient suspension of 4-bromo-2-fluorobenzoic acid (15.0 g, 68.5 mmol), iodomethane (21.0 mL, 342.5 mmol), and potassium carbonate (19.0 g, 137 mmol) inN.N-dimethylformamide (200 mL) was stirred at room temperature for 16 h, after which it was diluted with ethyl acetate (200 mL) and water (100 mL). The layers were separated, and the organics were washed with water (3 x 100 mL) and brine (1 x 100 mL), dried over sodium sulfate, and concentrated under reduced.pressure. The residue was passed through a plug of SiCh gel, eluting with 50% ethyl acetate in hexane, to give the title compound as a solid. MS (ESI) m/z 233 [M+H]+. Example 53B l-(4-bromo-2-fluorophenyl)cyclopentanol A 100 mL 3N round-bottom flask was charged with magnesium (0.700 mg, 23.8 mmol) and tetrahydrofuran (30 mL). The suspension was stirred and cooled to 0 °C. 1,4-Dibromobutane (1.65 mL, 13.94 mmol) was slowly added, and the solution was allowed to warm to room temperature. After 30 min, the solution was cooled to 0 °C, and Example 53A (1.00g, 4.29 mmol) in tetrahydrofuran (10 mL) was added dropwise. After 30min, the solution was allowed to warm to room temperature and was stirred for an additional 1 h. The solution was quenched by the careful addition of saturated NH4C1 and ethyl acetate (50 mL). The layers were separated, and the organics were washed with water (2 x 50 mL) and brine (1 x 50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on SiCh gel, eluting with 3% ethyl acetate in hexane, to give the title compound. MS (ESI) m/z 259 [M+H]+. Example 53C 2-(l -(4-bromo-2-fluorophenyl)cyclopentyloxy)acetic acid Example 53C was prepared according to the procedure described for Example 30B, substituting Example 53B for Example 30A. MS (ESI) m/z 317 [M+H]+. Example 53D 2-(l-(2-fluoro-4-(6-(3-(3-(trifluoromethyl)phenyl)ureido)pyridin-3-yl)phenyl)cyclobutoxy)acetic acid A mixture of Example 29A (0.37 g, 0.31 mmol), Example 53C (0.29 g, 0.31 mmol), potassium phosphate (0.474 g, 2.73 mmol), and l,l'-bis(di-fert-butylphosphino)ferrocene palladium(II) dichloride (0.03 g, 0.05 mmol), in a solvent mixture of 2:2:1 N,N-dimethylformamide/ethanol/water (10 mL) was heated to 90 °C for 1 h. The reaction was cooled to room temperature, and stirred for 16 h. The resulting suspension was poured into water (200 mL) and acidified with 1M HC1 to pH 1. The solid was filtered, washed with water, dried, and purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to provide the title compound. 1H NMR (300 MHz, DMSO-dg) δ ppm 1.63-1.75 (m, 2 H), 1.77-1.97 (m, 4 H), 2.25-2.40 (m, 2 H), 3.67 (s, 2 H), 7.32-7.42 (m, 1 H), 7.49-7.63 (m, 4 H), 7.63-7.72 (m, 2 H), 8.02-8.11 (m, 1 H), 8.12-8.22 (m, 1 H), 8.64-8.75 (m, 1 H), 9.69 (s, 1 H), 10.68 (s, 1 H); MS (ESI) m/z 518 [M+Hf. Example 54 l-(5-(4-(4-oxa-l-azabicyclo[3.2.1]octan-5-yl)phenyl)pyridin-2-yl)-3-phenylurea Example 54A tert-butyl 3-(4-bromophenyl)-3-hydroxypyrrolidine-1 -carboxylate To a cold (-78 °C) solution of 1,4-dibromobenzene (3.89 g, 16.49 mmol) in tetrahydrofuran (80 mL) was added n-butyllithium (10.3 mL, 16.5 mmol, 1.6 M in hexane) dropwise. After 15 minutes, a solution of tert-butyl 3-oxopyrrolidine-l-carboxylate (3.05 g, 16.49 mmol) in tetrahydrofuran (10 mL) was added over 5 minutes. The reaction continued to stir at -78 °C for 15 minutes and was then quenched by the addition of saturated NH4C1 (150 mL) and diethyl ether (150 mL). After warming to room temperature, the layers were separated, and the aqueous was extracted with additional diethyl ether (2 x 100 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by MPLC (10% ethyl acetate in hexane to 50% ethyl acetate in hexane) to give the title product. MS (ESI) m/z 342 [M+H]+. Example 54B tert-butyl 3-(4-bromophenyl)-3-(2-ethoxy-2-oxoethoxy)pyrrolidine-1 -carboxylate Example 5 IB was prepared according to the procedure described for Example 33B, substituting Example 54A for Example 33A. MS (ESI) m/z 428 [M+H]+. Example 54C ter/-butyl3-(4-bromophenyl)-3-(2-hydroxyethoxy)pyrrolidine-l-carboxylate To an ambient solution of Example 54B (0.530 g, 1.24 mmol) in methanol (5 mL) was added NaBtL; (0.188 g, 4.96 mmol). The reaction was stirred for 1 h and was then quenched by the addition of water (20 mL) and ethyl acetate (20 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 20 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the title compound, which was used in the subsequent step without further purification. MS (ESI) m/z 386 [M+H]+. Example 54D ferf-butyl3-(4-bromophenyl)-3-(2-(tosyloxy)ethoxy)pyrrolidine-l-carboxylate To an ambient solution of Example 54G (0.450 g, 1.17 mmol), triethylamine (0.178 mL, 1.28 mmol), and 4-dimethylaminopyridine (0.005 g, 0.041 mmol) in dichloromethane (3 mL) was added/?-toluenesulfonate chloride (0.224 g, 1.17 mmol). The reaction was stirred at room temperature for 8 h and was then partitioned between water (10 mL) and diethyl ether (10 mL). The layers were separated, and the aqueous was extracted with additional diethyl ether (2x10 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by MPLC (10% ethyl acetate in hexane to 25% ethyl acetate in hexane) to give the title product. MS (ESI) m/z 541 [M+H]+. Example 54E 5-(4-bromophenyl)-4-oxa-l -azabicyclo[3.2.1 ]octane To an ambient solution of Example 54D (0.100 g, 0.186 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (0.5 ml). The reaction was stirred for 0.5 h, and the solution was then carefully added to a slurry of K2CO3 (3.0 g, 21.7 mmol) in dichloromethane (10 mL). After the evolution of gas ceased, the mixture was heated to 40 °C for 1 h. The mixture was cooled to room temperature and was diluted with water (10 mL). The layers were separated, and the aqueous was extracted with additional dichloromethane (2x10 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the title product, which was used in the subsequent step without further purification. MS (ESI) m/z 268 [M+H]+. Example 54F 1 -(5 -(4-(4-oxa-1 -azabicyclo[3.2.1 ]octan-5 -yl)phenyl)pyridin-2-yl)-3 -phenylurea A solution of Example 54E (0.048 g, 0.18 mmol), Example 28A (0.063 g, 0.18 mmol), CsF (0.085 g, 0.559 mmol), and tetrakis(triphenylphosphine)palladium(O) (0.020 g, 0.017 mmol) in a solvent mixture of dimethoxyethane (0.5 mL) and methanol (0.5 mL) was heated to 90 °C for 16 h. The reaction was cooled to room temperature and diluted with H2O (2 mL) and ethyl acetate (2 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 2 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min). The fractions containing the desired product were diluted with saturated aqueous NaHCO3 and extracted with ethyl acetate. The organic layer was dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the title compound as a white solid. lH NMR (500 MHz, DMSO-d6) δ ppm 2.09-2.17 (m, 1 H), 2.27-2.38 (m, 1 H), 2.53-2.61 (m, 1 H), 2.81-2.88 (m, 1 H), 2.91-2.98 (m, 2 H), 3.02-3.09 (m, 1 H), 3.10-3.18 (m, 1 H), 3.69-3.79 (m, 1 H), 3.94-4.03 (m, 1 H), 6.99-7.07 (m, 1 H), 7.28-7.38 (m, 2 H), 7.48-7.57 (m, 4 H), 7.60-7.69 (m, 3 H), 8.02-8.12 (m, 1 H), 8.53-8.67 (m, 1 H), 9.45-9.58 (m, 1 H), 10.31-10.44 (m, 1 H); MS (ESI) m/z 401 [M+H]+. Example 55 2-(l-(3-fluoro-4-(6-(3-(3-(trifluoromethyl)phenyl)ureido)pyridin-3-yl)phenyl)cyclopentyloxy)acetic acid Example 55A l-(4-chloro-3-fluorophenyl)cyclopentanol Eaxample 58A was prepared according to the procedure described for Example 30A, substituting l-bromo-3-fluoro-4-chlorobenzene for 1,4-dibromobenzene. MS (ESI) m/z 215 [M+H]+. Example 55B 2-(l-(4-chloro-3-fluorophenyl)cyclopentyloxy)acetic acid Example 55B was prepared according to the procedure described for Example 30B, substituting Example 55A for Example 30A. MS (ESI) m/z 273 [M+H]+. Example 55C 2-( 1 -(3-fluoro-4-(6-(3-(3-(trifluoromethyl)phenyl)ureido)pyridin-3-yl)phenyl)cyclopentyloxy)acetic acid A mixture of Example 55B (0.094 g, 0.346 mmol), Example 29A (0.141 g, 0.346 mmol), K3PO4 (0.220 g, 1.04 mmol), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (0.019 g, 0.046 mmol), and tris(dibenzylideneacetone)dipalladium(O) (0.011 g, 0.012 mmol) in a solvent mixture of N,N-dimethylformamide/l-butanol/H20 (2/2/1, l mL) was heated to 90 °C for 15 h. The solution was cooled to room temperature and diluted with 10% HC1 (1 mL) and ethyl acetate (1 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2x2 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-Cl8 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to provide the title compound as a white solid. JH NMR (300 MHz, DMSO-dg) δ ppm 1.66-1.77 (m, 2 H), 1.80-1.91 (m, 4 H), 2.05-2.18 (m, 2 H), 3.69 (s, 2 H), 7.30-7.41 (m, 3 H), 7.50-7.64 (m, 2 H), 7.64-7.73 (m, 2 H), 7.94-8.03 (m, 1 H), 8.09 (s, 1 H), 8.47-8.56 (m, 1 H), 9.69 (s, 1 H), 10.65 (s, 1 H); MS (ESI) m/z518[M+H]+. Example 56 2-(l-(3-fluoro-4-(6-(3-(3-(trifluoromethyl)phenyl)ureido)pyridin-3- yl)phenyl)cyclobutoxy)acetic acid Example 56A l-(4-chloro-3-fluorophenyl)cyclobutanol To a cold (-78 °C) solution of 4-bromo-l-chloro-2-fluorobenzene (2.99 g, 14.27 mmol) in tetrahydrofuran (50 mL) was added n-butyllithium (5.71 mL, 14.27 mmol, 2.5 m in hexane) over 5 minutes. The reaction was stirred at -78 °C for 15 min, and cybutanone (1.0 g, 14.27 mmol) was added dropwise. After 15 minutes, the reaction mixture was quenched by the addition of saturated aqueous of NH4CI (50 mL) and diethyl ether (50 mL). The layers were separated, and the aqueous was extracted with additional diethyl ether (2 X 50 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered concentrated under reduced pressure. The residue was purified by RP-HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to provide the title compound as a solid. MS (ESI) m/z 201 [M+H]+. Example 56B 2-(l-(4-chloro-3-fluorophenyl)cyclobutoxy)acetic acid To an ambient suspension of NaH (0.341 g, 8.52 mmol, 60% dispersion in mineral oil) in N,N-dimethylformamide (7 mL) was added a solution of Example 56A (0.342 g, 1.71 mmol) in N,N-dimethylformamide (1 mL) dropwise. The reaction was stirred for 0.5 h, and 2-bromoacetic acid (0.474 g, 3.41 mmol) was added as a solution in N,N-dimethylformamide (2 mL) dropwise. The reaction was stirred at room temperature for 24 h and was then quenched by the slow addition of H2O (10 mL) and diethyl ether (15 mL). The layers were separated, and the organic discarded. The aqueous was acidified to pH -4-5 with 10% HG1 and was extracted with diethyl ether (3x15 mL). The combined organics were dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a yellow oil, which was used without further purification in the subsequent step. MS (ESI) m/z 259 [M+H]+. Example 56C 2-(l-(3-fluoro-4-(6-(3-(3-(trifluoromethyl)phenyl)ureido)pyridin-3-yl)phenyl)cyclobutoxy)acetic acid Example 56C was prepared according to the procedure described for Example 55C, substituting Example 56B for Example 55B. lH NMR (300 MHz, DMSO-d6) δ ppm 1.56-1.74 (m, 1 H), 1.84-2.01 (m, 1 H), 2.33-2.45 (m, 4 H), 3.68 (s, 2 H), 7.34-7.44 (m, 3 H), 7.52-7.64 (m, 2 H), 7.64-7.73 (m, 2 H), 7.95-8.05 (m, 1 H), 8.09 (s, 1 H), 8.52-8.57 (m, 1 H), 9.67 (s, 1 H), 10.64 (s, 1 H); MS (ESI) m/z 504 [M+H]+. Example 57 [(l-{5-[4-({[(2-fluorophenyl)ainino]carbonyl}amino)phenyl]pyridin-2- yl}cyclopentyl)oxy]acetic acid Example 57A l-(5-(4-Nitrophenyl)pyridin-2-yl)cyclopentanol To a cold (-20 °C) solution of 5-bromo-2-iodopyridine (10 g, 35.22 mmol) in tetrahydrofuran (50 mL) was added isopropylmagnesium chloride (20 mL, 38.74 mmol, 2 M solution in tetrahydrofuran) dropwise over 10 minutes. The reaction was allowed to warm to 0 °C over 1 hour and then cooled to -15 °C. A solution of cyclopentanone (2.7 mL, 30 mmol) in tetrahydrofuran (25 mL) was added dropwise, and the reaction was warmed to 15 °C over 3 hours. The reaction was then quenched by the dropwise addition of saturated aqueous NH4CI. The layers were separated, and the aqueous was extracted with ethyl acetate (3 X 30 mL). The combined organic layers were washed with water, brine, dried with anhydrous MgSO4, filtered and concentrated under reduced pressure to provide a crude alcohol, which was used in the subsequent step without further purification. A mixture of the crude alcohol (1.05 g, 4.34 mmol), 4-nitrophenyl boronic acid pinacol ester (1.4 g, 5.64 mmol), potassium fluoride (0.76 g, 13 mmol) and tetrakis(triphenylphosphine) palladium (0.87 g, 0.43 mmol) in a solvent mixture (dimethoxyethane:ethanol:water:toluene, 10:6:3:1, 50 mL) was heated to 90 °C for 10 hours. The reaction was cooled to room temperature, diluted with water, and extracted with ethyl acetate (3 X 50 mL). The combined organic layers were washed with water, brine, dried with anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by chromatography on S1O2 (30 % ethyl acetate in hexane) to afford the title compound. 1HNMR (300 MHz, DMSO-d6) δ ppm 1.70-1.82 (m, 4H), 1.84-1.93 (m, 2 H), 2.08-2.18 (m, 2 H), 5.15 (s, 1 H), 7.81 (m, 1 H), 8.02 (m, 2 H), 8.17 (m, 1 H), 8.32 (m, 2 H), 8.91 (m, 1 H). Example 57B Methyl 2-(l -(5-(4-nitrophenyl)pyridin-2-yl)cyclopentyloxy)acetate To an ambient suspension of sodium hydride (0.2 g, 60% suspension in mineral oil, 4.85 mmol) in N,N-dimethylformamide (3 mL) was added a solution of Example 57A (0.46 g, 1.6 mmol) in N,N-dimethylformamide (4 mL) at room temperature. After 20 minutes, allyl bromide (0.42 mL, 4.85 mmol) was added, and the reaction was stirred at room temperature for 3 hours. The reaction was then quenched by the addition of saturated aqueous NH4CI. The layers were separated, and the aqueous was extracted with ethyl acetate (3 X 50 mL). The combined organic layers were washed with water, brine, dried with anhydrous MgSO4, filtered and concentrated under reduced pressure to provide a crude allyl ether, which was used in the next step without further purification. The crude product from the previous step was dissolved in glacial acetic acid (20 mL) and added to a cold (0 °C) solution of potassium permanganate (1 g, 6.44 mmol) in water (20 mL). The reaction was warmed to room temperature over 20 minutes and was then quenched by the addition of benzene (25 mL) and solid sodium sulfite (15 g). The biphasic mixture was acidified to pH 3 by the addition of 3N HC1 and extracted with ethyl acetate (3 X 50 mL). The combined organic layers were washed with water, brine, dried with anhydrous MgSO4, filtered and concentrated under reduced pressure to provide a crude acid, which was used in the next step without further purification. The crude acid was dissolved in benzene (25 mL) and methanol (15 mL), and a solution of (trimethylsilyl)diazomethane (1.61 mL, 2M solution in hexanes) was added dropwise at room temperature over 10 minutes. The reaction was then quenched by the drop wise addition of acetic acid, and the solvents were removed under reduced pressure. The residue was treated with saturated aqueous sodium bicarbonate and extracted with ethyl acetate (3X30 mL). The combined organic layers were washed with water, brine, dried with anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by chromatography on Si02 (30 % ethyl acetate in hexane) to afford the title compound as an oil. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.70-1.79 (m, 2H), 1.81-1.91 (m, 2 H), 2.03-2.15 (m, 4 H), 3.62 (s, 3 H), 3.91 (s, 2 H), 7.69 (m, 1 H), 8.05 (m, 2 H), 8.24 (m, 1 H), 8.33 (m, 2 H), 8.97 (broad s, 1 H); MS (ESI) m/z 357 [M+H]+. Example 57C [(1 - {5-[4-( {[(2-fluorophenyl)amino]carbonyl} amino)phenyl]pyridin-2- yl}cyclopentyl)oxy]acetic acid A suspension of Example 57B (0.15 g, 0.42 mmol), iron powder (0.047 g, 0.84 mmol) and ammonium chloride (0.026 g, 0.46 mmol) in ethanol (10 mL) and water (5 mL) was heated to reflux for 1 h. The reaction was cooled and filtered through a pad of wet celite. The filtrate was diluted with ethyl acetate, and the layers were separated. The combined organic layers were washed with water, brine, dried with anhydrous MgSO4, filtered and concentrated under reduced pressure to provide a crude ester, which was used in the next step without further purification. To an ambient solution of the crude ester (0.05 g, 0.15 mmol) from the previous step in tetrahydrofuran (5 mL) was added 2-fluorophenyl isocyanate (0.034 mL, 0.3 mmol). The reaction was stirred at room temperature for 15 hours, diluted with water and extracted with ethyl acetate (3 X 25 mL). The combined organic layers were washed with water, brine, dried with anhydrous MgSO4, filtered and concentrated under reduced pressure to provide a residue, which was used in the next step without further purification. Lithium hydroxide monohydrate (0.02 g) was added to the solution of the crude product in tetrahydrofuran (10 mL) and water (5 mL) and stirred at room temperature for 12 hours. The reaction was acidified (pH 1) by the addition of 3N HC1 and extracted with ethyl acetate (3 X 25 mL). The combined organic layers were washed with water, brine, dried with anhydrous MgSO4, filtered and concentrated under reduced pressure to provide a yellow solid. This solid was recrystallized using methanol/ethyl acetate to afford the title compound as a pale yellow solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.68-1.78 (m, 2H), 1.81-1.90 (m, 2 H), 2.01-2.15 (m, 4 H), 3.77 (s, 2 H), 7.00-7.04 (m, 1 H), 7.15 (m, 1 H), 7.24 (m, 1 H), 7.59 (d, J= 8.55 Hz, 2 H), 7.62 (m, 1 H), 7.70 (m, 2 H), 8.07 (m, 1 H), 8.16 (m, 1 H), 8.60 (m, 1 H), 8.81 (m, 1 H), 12.62 (broad s, 1 H); MS (ESI) m/z 450.1 [M+H]+. Example 58 [l-(4- {6-[({[3-(trifluoromemyl)phenyl]arnmo}carbonyl)amino]pyridin-3- yl}phenyl)cyclopentyl]acetic acid Example 58A ethyl 2-cyano-2-cyclopentylideneacetate To an ambient solution of hexamethyldisilazane (17.7 mL, 84.0 mmol) in acetic acid (56 mL) was added sequentially cyclopentanone (5.0 mL, 56.3 mmol) and ethyl 2-cyanoacetate (12.0 mL, 113 mmol). The solution was heated to 70 °C for 15 hours. The reaction was cooled to room temperature and diluted with water (100 mL) and ethyl acetate (100 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 100 mL). The combined organics were dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on SiO2 gel, eluting with 100% hexane to 5% ethyl acetate in hexane, to give the title product as a white solid. MS (ESI) m/z 180 [M+H]+. Example 58B 2-(l-(4-chlorophenyl)cyclopentyl)-2-cyanoacetic acid To an ambient suspension of magnesium turnings (0.43 g, 17.7 mmol) in tetrahydrofuran (20 mL) was added 4-bromo-l-chloro-benzene (0.4 g, 2.08 mmol) and a few crystals of iodine. The reaction was gently warmed with a heat gun. After the purple color dissipated, the remainder of the 4-bromo-l-chloro-benzene (2.0 g, 15.6 mmol) was added to the reaction dropwise as a solution in tetrahydrofuran (20 mL) at such a rate to maintain a gentle reflux. After 1 h, the solution of the Grignard of 4-bromo-l-chloro-benzene was cooled to ambient temperature and added dropwise to a cold (0 °C) mixture of Cul (0.237 g, 1.24 mmol) and Example 58A (3.18 g, 17.7 mmol) in tetrahydrofuran (20 mL). The reaction was stirred at 0 °C for 0.5 h. The cooling bath was removed, and the reaction was stirred at ambient temperature for 15 h. The reaction was then quenched by the addition of saturated aqueous NH4CI (100 mL) and ethyl acetate (100 mL). The layers were separated, and the aqueous was extracted with additional ethyl acetate (2 x 50 mL). The combined organic layers were dried with anhydrous Na2SO»4, filtered and concentrated under reduced pressure. The residue was purified by chromatography on Si02 gel, eluting with 100% hexane to 10% ethyl acetate in hexane, to give the title compound. MS (ESI) m/z 293 [M+H]+. Example 58C 2-( 1 -(4-chlorophenyl)cyclopentyl)acetic acid Example 58B (3.0 g, 10.3 mmol) was dissolved in a 15% w/w solution of KOH in ethylene glycol (50 mL) and heated to 190 °C for 4 hours. The reaction was cooled to room temperature, diluted with water (100 mL), and the pH adjusted to ~3 with concentrated HC1. The aqueous was extracted with dichloromethane (3 x 50 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by RP- HPLC (preparative reversed-phase high pressure liquid chromatography) using a Zorbax SB-C18 7M 21.2x250 mm column with UV detection analyzed at 220 and 254 nM (preparative method: water with 0.1% trifluoroacetic acid and CH3CN with 0.1% trifluoroacetic acid gradient 5-95% CH3CN over 30 minutes at 15 mL/min) to give the title compound as a beije solid. MS (ESI) m/z 238 [M-H]". Example 58D [l-(4-{6-[({[3-(trifluoromemyl)phenyl]ammo}carbonyl)amino]pyridin-3-yl}phenyl)cyclopentyl]acetic acid Example 58D was prepared according to the procedure described for Example 55C, substituting Example 58C for Example 55B. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.52-1.84 (m, 4 H), 1.85-2.14 (m, 4 H), 2.56-2.67 (m, 2 H), 7.35-7.51 (m, 3 H), 7.53-7.65 (m, 3 H), 7.67-7.73 (m, 1 H), 7.76-7.85 (m, 1 H), 8.05-8.16 (m, 2 H), 8.63 (m, 1 H), 9.56-9.68 (m, 1 H), 10.66-10.81 (m, 1 H), 11.80 (s, 1 H); MS (ESI) m/z 484 [M+H]+. Example 59 (l-{4-[6-({[(2-fluorophenyl)amino]carbonyl}amino)pyridin-3-yl]phenyl}cyclopentyl)acetic acid Example 59A l-(2-fluorophenyl)-3-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl)urea Example 59A was prepared according to the procedure described for Example 28A, substituting 2-fluorophenyl isocyanate for phenyl isocyanate. MS (ESI) m/z 358 [M+H]+. Example 59B (1 - (4-[6-( {[(2-fluorophenyl)amino]carbonyl} amino)pyridin-3-yl]phenyl} cyclopentyl)acetic acid Example 59B was prepared according to the procedure described for Example 55C, substituting Example 58C for Example 55B and substituting Example 59A for Example 29A. 'H NMR (300 MHz, DMSO-d6) δ ppm 1.46-1.83 (m, 4 H), 1.85-2.11 (m, 4 H), 2.54-2.69 (m, 2 H), 7.00-7.11 (m, 1 H), 7.17 (m, 1 H), 7.23-7.32 (m, 1 H), 7.43 (m, 2 H), 7.54 (m, 1 H), 7.61 (m, 2 H) δ.09 (m, 1 H,) δ.16-8.33 (m, 1 H), 8.58 (m, 1 H), 9.89 (s, 1 H), 10.76 (s, 1 H), 11.82 (s, 1 H); MS (ESI) m/z 434 [M+H]+. Compound 60 {[l-(2-fluoro-4-{6-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]pyridin-3- yl}phenyl)cyclobutyl]oxy} acetic acid Example 60A l-(4-bromo-2-fluorophenyl)cyclobutanol A 100 mL 3-neck round bottom flask was charged with 4-bromo-2-fiuoro-l -iodobenzene (1000 mg, 3.32 mmol) and diethyl ether (30 mL). The solution was cooled to -78 °C, and n-butyllithium (1.329 mL, 3.32 mmol) was added dropwise, keeping the temperature below -68°C. After stirring for 15 min, cyclobutanone (0.249 mL, 3.32 mmol) was added dropwise, keeping temperature below -68°C. The solution was stirred at -78 °C for 15 min. The reaction was then quenched by the addition of saturated ammonium chloride (25 mL). The layers were separated, and the organic was washed with water (1 x 10 mL) and brine (1x10 mL). The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography (SiO2 gel), eluting with 3% ethyl acetate / hexanes to give the desired product. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.55-1.69 (m, 1 H), 1.91.2.05 (m, 1 H), 2.19-2.28 (m, 2 H), 2.46-2.55 (m, 2 H), 5.59 (s, 1 H), 7.33-7.40 (m, 2 H), 7.44-7.48 (m, 2 H). Example 60B {[1-(4-bromo-2-fluorophenyl)cyclobutyl]oxy} acetic acid A 50 mL round-bottomed flask was charged with NaH (361 mg, 9.04 mmol) and N,N-dimethylacetamide (5mL). A solution of the product from Example 60A (443 mg, 1.808 mmol) in N,N-dimethylacetamide (5mL) was added dropwise, and the reaction was stirred at 22°C for 30 min. A solution of 2-bromoacetic acid (502 mg, 3.62 mmol) in N,N- dimethylacetamide (5mL) was added dropwise. The reaction was stirred at 22 °C for 16 hours and was then quenched by the slow addition of water (15 mL). The aqueous was extracted with 1:1 diethyl ether/hexanes (2 x 20 mL), and the organics discarded. The aqueous layer was acidified to pH 1 with 1M HO and extracted with ethyl acetate (2 x 75 mL). The combined organics were washed with water (4 x 20 mL) and brine (1 x 20 mL), dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the title product. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.54-1.70 (m, 1 H), 1.91-2.10 (m, 1 H), 2.34-2.47 (m, 4 H), 3.65 (s, 2 H), 7.34-7.43 (m, 2 H), 7.49-7.53 (m 1 H), 12.45 (s, 1 H). Example 60C N-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl]-A',-[3-(trifluoromethyl)phenyl]urea To an ambient solution of 5T(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.350 g, 1.59 mmol) in tetrahydrofuran (4 mL) was added 3-trifluoromethylphenyl isocyanate (1.59 mmol). The solution was stirred at room temperature for 1 hour and was then concentrated under reduced pressure. The solid was washed with diethyl ether (2 mL) and air-dried to give the title compound. MS (ESI) m/z 408 [M+H]+. Example 60D {[l-(2-fluoro-4-{6-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]pyridin-3-yl}phenyl)cyclobutyl]oxy} acetic acid A 25 mL vial was charged with the product from Example 60C (459 mg, 1.128 mmol), the product from Example 60B (342 mg, 1.128 mmol), dibasic potassium phosphate (590 mg, 3.38 mmol), and l,r-bis(di-tert-butlyphosphino)ferrocene palladium (II) dichloride (7.38 mg, 0.011 mmol), N,N-dimethylacetamide (4 mL), ethanol (4.00 ml) and water (2 mL). The suspension was stirred and heated to 90 °C, whereupon the reaction became homogenous. After heating at 90 °C for 1 hour, the reaction was cooled to room temperature. The resulting suspension was poured into water (200 mL). The mixture was acidified to pH 1 with 1 M HC1. The solid was filtered, washed with water, and air-dried to give the title product. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.62-1.71 (m, 1 H), 1.96-2.07 (m, 1 H), 2.39-2.49 (m, 4 H), 3.69 (s, 2 H), 7.38 (d, J= 7.12 Hz, 1 H), 7.47-7.61 (m, 4 H), 7.65-7.71 (m, 2 H), 8.07 (s, 1 H), 8.17 (dd, J= 2.7 and 8.8 Hz, 1 H), 8.71 id, J =2.1 Hz, 1 H), 9.68 (s, 1 H), 10.65 (s, 1 H), 12.5 (br s, 1 H). MS (ESI) m/z 504 [M+H]+. Example 61 [(1 - {2-fluoro-4-[6-( {[3-(trifluoromethyl)phenyl]acetyl}amino)pyridin-3- yl]phenyl}cyclobutyl)oxy]acetic acid Example 61A 6-({[3-(trifluoromethyl)phenyl]acetyl}amino)pyridin-3-ylboronic acid A 250 mL round-bottomed flask was charged with 2-(3-(trifluoromethyl)phenyl)acetic acid (2.319 g, 11.36 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridm-2-amine (2.5 g, 11.36 mmol), l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (2.178 g, 11.36 mmol), 1-hydroxybenzotriazole hydrate (1.740 g, 11.36 mmol), N-methylmorpholine (5.00 mL, 45.4 mmol) and N,N-dimethylacetamide (50 mL). The reaction was stirred at 50 °C for 16 hours. The reaction was then quenched by the addition of ethyl acetate (50 mL) and water (50 mL). The layers were separated, and the organic was washed with water (3 x 50 mL) and brine (1 x 50 mL). The organic was dried with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse-phase HPLC using a 15% water (0.1% trifluoroacetic acid) to 95% acetonitrile (0.1% trifluoroacetic acid) gradient to give the boronic acid as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.88 (s, 2 H), 7.54-7.66 (m, 3 H), 7.72 (s, 1 H), 7.96 (d, J= 8.5 Hz, 1 H), 8.12 (dd, J= 1.7 and 8.1 Hz, 1 H), 8.4 (br s, 1 H), 10.94 (s, 1 H). Example 61B [(1 - {2-fluoro-4-[6-( {[3-(trifluoromethyl)phenyl]acetyl} amino)pyridin-3-yi]phenyl}cyclobutyl)oxy]acetic acid A 4mL vial was charged with the product from Example 61A (17.7 mg, 0.055 mmol) and the product from Example 60B (16.56 mg, 0.055 mmol), dibasic potassium phosphate (28.5 mg, 0.164 mmol), l,r-bis(di-tert-butlyphosphino)ferrocene palladium (II) dichloride (0.357 mg, 0.546 µmol), N,N-dimethylacetamide (1 ml), ethanol (1.000 mL), and water (0.500 mL). The suspension was stirred and heated to 90 °C, whereupon the reaction became homogenous. After heating at 90 °C for 1 hour, the reaction was cooled to room temperature. The reaction was then partitioned between with ethyl acetate (2 mL) and water (2 mL). The layers were separated, and the organic was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse-phase HPLC (mobile phase: 10% -100% acetonitrile in 0.1% trifluoroacetic acid aqueous solution during 60 min, C18 column) to give the title product. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.59-1.72 (m, 1 H), 1.95-2.07 (m, 1 H), 2.38-2.45 (m, 4 H), 3.65 (s, 2 H), 3.89 (s, 2 H), 7.46-7.52 (m, 1 H), 7.55-7.67 (m, 5 H), 7.73 (s, 1 H), 8.11-8.18 (m, 2 H), 8.73 (br s, 1 H), 10.94 (s, 1 H). MS (ESI) m/z 503 [M+H]+. It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations upon the scope of the invention. Various changes and modifications including, but not limited to, those relating to the chemical structures, substituents, derivatives, intermediates, syntheses, formulations and/or methods of use of the invention, can be made without departing from the spirit of the present invention and scope thereof. We claim: 1. A compound of formula (I), (Formula Removed) or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein: G1 is phenyl or monocyclic heteroaryl, each of which is optionally further substituted with 1, 2, 3, or 4 substituents as represented by T; G2 is phenyl or monocyclic heteroaryl, each of which is optionally further substituted with 1,2, 3, or 4 substituents as represented by T; T, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, -CN, -N02, -OR1, -OC(O)(R2), -N(Rw))(R1), -N(RW)C(O)(R1), -N(Rw)-C(O)O(R1), -N(Rw)-C(O)N(Rw)(R1), -N(Rw)-S(O)2(R2), -C(O)O(CR1), -C(O)N(Rw)(R1), -C(O)R1, -SR1, -S(O)R2, -S(O)2R2, -S(O)2N(Rw)(R1), -(CR8Rb)r-CN, -(CRaRb)rN02, -(CR'RVOR1, -(CRaRVOC(O)(R2), -(CR"Rb)rN(Rw)(R1), -(CRaRb)r-N(Rw)C(O)(R1),-(CRaRb)r-N(Rw)-C(O)O(R1),-(CRaRb)r-N(Rw)-C(O)N(Rw)(R1), -(CRaRb)I-N(Rw)-S(O)2(R2),-(CRaRb)r-C(O)O(R1),-(CRaRb)r-C(O)N(Rw)(R1), -(CRaRb)r-C(O)R1, -(CRARB)R-SR1, -(CRaRVS(O)R2, -(CRaRVS(O)2R2, -(CRARB)R-S(O)2N(RW)CR1), and haloalkyl; or two of the adjacent substituents T, together with the carbon atoms to which they are attached, form a monocyclic ring selected from the group consisting of phenyl, heterocycle and heteroaryl, wherein each ring is optionally further substituted with 1,2 or 3 substituents selected from the group consisting of oxo, alkyl, alkenyl, alkynyl, halogen, -CN, -N02, -OR1, -OC(O)(R2), -N(Rw)(R1), -N(Rw)C(O)(R1), -N(Rw)-C(O)O(R1), -N(Rw)-C(O)N(Rw)(R1), -N(Rw)-S(O)2(R2), -C(O)O(Rl), -C(O)N(Rw)(R1), -C(O)R1, -SR1, -S(O)R2, -S(O)2R2, -S(O)2N(Rw)(R1), -(CRaRb)r-CN, -(CRaRb)r-NO2, -(CRgRh)r-OR1, -(CRaRb)OC(O)(R2), -(CRARB)R-N(RW)(R1), -(CRARB)R-N(RW)C(O)(R1), -(CRaRb)r-N(Rw)-C(O)O(R1), -(CRaRb)r-N(Rw)-C(O)N(Rw)(R1), -(CRaRVN(Rw)-S(O)2(R2), -(CRaRb)rC(O)O(R1), -(CRaRb)r-C(O)N(Rw)(R1), -(CRaRb)r-C(O)R1, -(CRaRb)r-SR1, -(CRaRVS(O)R2, -(CRaRVS(O)2R2,-(CRaRb)r-S(O)2N(Rw)(R1), and haloalkyl; G3 is formula (a) or formula (b) (Formula Removed) W1 is -C(R3)(R4)- or -C(R3)(R4)-C(R3)(R4)-, and W2 is -C(R7)- or N; or W1 is N(H), N(alkyl), O, S(O), or S(O)2, and W2 is -C(R7)-; W3 is N(H),N(alkyl),or O; W4 is -C(R3)(R4)- or -C(R3)(R4)-C(R3)(R4)-; R3 and R4, at each occurrence, are independently hydrogen or C1-6 alkyl; R5 and R6 are independently hydrogen or C1-6 alkyl; or R5 and R6, together with the carbon to which they are attached, is C(=O); R7, at each occurrence, is independently hydrogen, C1-6 alkyl or -C(O)OH; Rc and Rd, together with the carbon atom to which they are attached, is a 3- to 6-membered cycloalkyl or a monocyclic heterocycle of formula (c); (Formula Removed) wherein 1,2, 3, or 4 hydrogen atoms attached to the ring carbon of the cycloalkyl and the monocyclic heterocycle are optionally replaced with radicals selected from the group consisting of alkyl, halogen, -CN, haloalkyl, -C(O)O(R8), -C(O)N(R8)(R9), -(CReRf),-C(O)O(R8), and -(CReRf)t-C(O)N(R8)(R9); W5 is -CH2- or -CH2-CH2-; W6 is O, S, S(O), S(O)2, N(RX), -C(O)N(Ry)- or -N(Ry)C(O)-; wherein RX is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl, cycloalkenylalkyl, arylalkyl, heteroarylalkyl, heterocyclealkyl, -C(O)O(Rz), -C(O)Rz, or-C(O)N(Rw)(Rm); Ry and Rm, at each occurrence, are each independently hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycle, arylalkyl, cycloalkylalkyl, cycloalkenylalkyl, heteroarylalkyl, or heterocyclealkyl; Rz, at each occurrence, is independently alkyl, haloalkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycle, arylalkyl, cycloalkylalkyl, cycloalkenylalkyl, heteroarylalkyl, or heterocyclealkyl; R8 and R9, at each occurrence, are independently hydrogen, alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycle, haloalkyl, arylalkyl, cycloalkylalkyl, cycloalkenylalkyl, heteroarylalkyl, or heterocyclealkyl; or R8 and R9, together with the nitrogen atom to which they are attached, form a heterocycle ring, optionally further substituted with 1, 2 or 3 substituents selected from the group consisting of alkyl, halogen, and haloalkyl; L1 is O, N(H), or N(alkyl); and X is -(CRgRh)u-tertrazolyl, heterocyclealkyl, heteroarylalkyl, hydrogen, alkyl, haloalkyl, -C(O)O(R10), -C(O)N(R10)(Rn), -(CR8Rh)u-OR10, -(CRGRH)U-N(R10)(R11), -(CRgRh)u-CN, -(CRgRhVC(O)O(R10), or -(CRgRVC(O)N(R10)(Rn); or L1 is -(CRPRq) and X is -C(O)OH or tetrazolyl; R10 and R11, at each occurrence, are independently hydrogen, alkyl, cycloalkyl, cycloalkenyl, heteroaryl, aryl, heterocycle, cycloalkylalkyl, cycloalkenylalkyl, heteroarylalkyl, arylalkyl, heterocyclealkyl, or haloalkyl; or R10 and R11, together with the nitrogen atom to which they are attached, form a heterocycle ring which is optionally further substituted with 1, 2, or 3 substituents selected from the group consisting of alkyl, halogen and haloalkyl; Q is alkyl, alkenyl, alkynyl, haloalkyl, G4, -Y1-Y3, or -Y1-(CRJRK)V-Y2-Y4; or Q is formula (d) (Formula Removed) Z is alkyl, alkenyl, alkynyl, haloalkyl, G4, -Y'-Y3, or -Y'-CCR^VY2-Y4; G is cycloalkyl, cycloalkenyl, heterocycle, heteroaryl, aryl, cycloalkylalkyl, cycloalkenylalkyl, heterocyclealkyl, heteroarylalkyl, or arylalkyl; Y1, at each occurrence, is independently -C(O)-, -C(O)0-, -C(O)N(Rw>, -S(O)2-, -S(O)2-N(Rw)-, wherein the right side of the -C(O)0-, -C(O)N(R>, and -S(O)2-N(Rw)-moieties are attached to Y3 or (CR'R^v, Y2 at each occurrence is independently 0, N(RW), or C(O); Y3 at each occurrence is independently alkyl, haloalkyl, cycloalkyl, cycloalkenyl, heterocycle, heteroaryl, aryl, cycloalkylalkyl, cycloalkenylalkyl, heterocyclealkyl, heteroarylalkyl or arylalkyl; Y4 at each occurrence is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkenyl, heterocycle, heteroaryl, aryl, cycloalkylalkyl, cycloalkenylalkyl, heterocyclealkyl, heteroarylalkyl, or arylalkyl; wherein the cycloalkenyl, cycloalkyl, heterocycle, heteroaryl, aryl, the aryl moiety of the arylalkyl, the heteroaryl moiety of the heteroarylalkyl, the cycloalkyl moiety of the cycloalkylalkyl, the heterocycle moiety of the heterocyclealkylalkyl, and the cycloalkenyl moiety of the cycloalkenylalkyl as represented by X, G4, Y3, Y4, R\ Ry, Rz, Rm, R8, R9, R10, and Ru, are each optionally further substituted with 1, 2,3,4 or 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, oxo, ethylenedioxy, methylenedioxy, -CN, -N02, -OR1, -OC(O)(R2), -N(RW)(R!), -NCR^OXR1), -NCO-CCOJOCR1), -N(Rw)-C(O)N(Rw)(R1), -N(Rw)-S(O)2(R2), -C(O)O(R1), -C(O)N(RwXRI), -CCOR1, -SR1, -S(O)R2, -S(O)2R2, -S(O)2N(Rw)(R1), haloalkyl, -(CRaRb)r-CN, -(CRaRb)r-NO2, -(CRaRb)r-OR1, -(CRab)r-C(O)(R2), -(CRaRb)r-N(RwR1), -(CRARB)R-N(RW)C(O)(R1), -(CRaRb)r-N(Rw)-C(O)O(R1), -(CRaRb)I-N(Rw)-C(O)N(Rw)(R1), -(CRaRVN(Rw)-S(O)2(R2), -(CRaRb)r-C(O)O(R1), -(CRaRb)r-C(O)N(Rw)(R1), -(CRaRb)I-C(O)R1, -(CRaRb)r-SR1, -(CRaRb)r-S(O)R2, -(CRaRVs(O)2R2, -(CRaRb)I-S(O)2N(Rw)(R1), and haloalkyl; Ra, Rb, Re, Rf, R8, Rh, Rj, Rk, Rp, and Rq, at each occurrence, are independently hydrogen, halogen, alkyl, or haloalkyl; R and Rw, at each occurrence, are independently hydrogen, alkyl, or haloalkyl; R , at each occurrence, is independently alkyl or haloalkyl; and r, s,t,u, and v, at each occurrence, is independently 1,2, 3, 4, 5 or 6. 2. The compound of claim 1 comprising formula (II), (Formula Removed) or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. 3. The compound of claim 2 or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein W is N. 4. The compound of claim 1 comprising formula (III), (Formula Removed) or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. 5. The compound of claim 4, or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein L1 is O and X is hydrogen or alkyl. 6. The compound of claim 4, or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein L1 is 0 and X is -(CRgRh)u-C(O)O(R10). 7. The compound of claim 6, or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein Rg and Rh are each independently hydrogen or alkyl, u is 1 and R10 is hydrogen. 8. The compound of claim 6, or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein Rc and Rd, together with the carbon atom to which they are attached, is a 3-6 membered cycloalkyl wherein 1,2, 3, or 4 hydrogen atoms attached to the ring carbon of the cycloalkyl ring are optionally replaced with radicals selected from the group consisting of alkyl, halogen, -CN, haloalkyl, -C(O)O(R8), -C(O)N(R8)(R9), -(CReRf),-C(O)O(R8), and -(CReRf),-C(O)N(R8)(R9). 9. The compound of claim 6, or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein Rc and Rd, together with the carbon atom to which they are attached, is a monocyclic heterocycle of formula (c) wherein 1,2, 3, or 4 hydrogen atoms attached to the ring carbon of the monocyclic heterocycle ring are optionally replaced with radicals selected from the group consisting of alkyl, halogen, -CN, haloalkyl, -C(O)O(R8), -C(O)N(R8)(R9), -(CReRf),-C(O)O(R8), and -(CReRf)t-C(O)N(R8)(R9). 10. The compound of claim 9, or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein W6 is O or N(RX). 11. The compound of claim 4, or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein L1 is -(CRpRq)s- and X is -C(O)OH. 12. The compound of claim 1 selected from the group consisting of: N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)- 1,3-thiazol-5-yl]phenyl}urea; N- {4-[2-(1-ethyl-4-hydroxypiperidin-4-yl)-1,3-thiazol-5-yl]phenyl} -N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea; 4-(5-{4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]-3-fluorophenyl}-1,3-thiazol-2-yl)tetrahydro-2H-pyran-4-ol; 4-{5- {4-[(7-methyl-1,3-benzoxazol-2-yl)amino]phenyl}-1,3-thiazol-2-yl)tetrahydro-2H-pyran-4-ol; 4-(5-{2-chloro-4-[(7-chloro-1,3-benzoxazol-2-yl)amino]phenyl}-1,3-thiazol-2-yl)tetrahydro-2H-pyran-4-ol; 4-(5- {4-[(7-chloro-1,3-benzoxazol-2-yl)amino]-2-methylphenyl}-1,3-thiazol-2-yl)tetrahydro-2H-pyran-4-ol; N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{6-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-l,3-thiazol-5-yl]pyridin-3-yl}urea; N- {4-[2-(1-ethyl-4-hydroxypiperidin-4-yl)-1,3-thiazol-5-yl]-2-fluorophenyl} -N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea; N-(2,5-difluorophenyl)-N'- {4-[2-(l -ethyl-4-hydroxypiperidin-4-yl)-1,3-thiazol-5-yl]-2-fluorophenyl}urea; N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{6-[2-(l-hydroxycyclopentyl)-1,3-thiazol-5-. yl]pyridin-3-yl}urea; phenyl 4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-1,3-thiazol-5-yl]phenylcarbamate; N- {4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-1,3-thiazol-5-yl]phenyl}piperidine-1 -carboxamide; tert-butyl 3-(5- (4-[({[2-fluoro-5-(trifluoromethyl)phenyl]ammo}carbonyl)amino]phenyl}-1,3-thiazol-2-yl)-3- hydroxypyrrolidine-1 -carboxylate; N-[2-fluoro-5-(trifluoromethyl)phenyl]-N,-{4-[2-(3-hydroxypyrrolidin-3-yl)-1,3-thiazol-5-yl]phenyl}urea; N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{4-[2-(3-hydroxy-l-methylpyrrolidin-3-yl)-1,3-tbiazol-5-yl]phenyl}urea; N-{4-[2-(l-ethyl-3-hydroxypyrrolidin-3-yl)-l)3-thiazol-5-yl]phenyl}-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea; N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'- {4-[2-( 1 -hydroxycyclopentyl)-1,3-thiazol-5-yl]phenyl}urea; N- {4-[2-(1-hydroxycyclopentyl)-1,3-thiazol-5-yl]phenyl} -N'-[3-(trifluoromethyl)phenyl]urea; N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'- (4-[2-(1 -hydroxycyclobutyl)-1,3-thiazol-5-yl]phenyl}urea; N-{4-[2-(1-hydroxycyclobutyl)-l,3-thiazol-5-yl]phenyl}-N'-[3-(trifluoromethyl)phenyl]urea; (±)-Cis-3-hydroxy-3-{4'-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]-l,r-biphenyl-4-yl} cyclopentanecarboxylic acid; N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-{4-[2-(l-methoxycyclopentyl)-1,3-tbiazol-5-yl]phenyl}urea; {[l-(5-{4-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)aniino]phenyl}-1,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid; {[l-(5-{4-[(bicyclo[4.2.0]octa-1,3,5-trien-7-ylcarbonyl)amino]phenyl}-1,3-tbJazol-2-yl)cyclobutyl]oxy} acetic acid; ({1 -[5-(4- {[(2-fluorophenyl)acetyl]amino}phenyl)-1,3-thiazol-2-yl]cyclobutyl}oxy)acetic acid; {[l-(5-{4-[(anilinocarbonyl)amino]phenyl}-1,3-thiazol-2-yl)cyclopentyl]oxy}acetic acid; {[l-(5-{4-[(anilinocarbonyl)amino]phenyl}-1,3-thiazol-2-yl)cyclobutyl]oxy}acetic acid; {[1 -(5- {6-[(anilinocarbonyl)amino]pyridin-3-yl}-1,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid; {[l-(5-{6-[({[3-(trifluoromethyl)phenyl]ammo}carbonyl)arnino]pyridin-3-yl}-1,3-hiazol-2-yl)cyclopentyl]oxy} acetic acid; {[l-(4-{6-[(anilinocarbonyl)amino]pyridin-3-yl}phenyl)cyclopentyl]oxy}acetic acid; (±)-Cis-3-(4'-{[(2-fluorophenyl)acetyl]amino}-1,1'-biphenyl-4-yl)-3- hydroxycyclopentanecarboxylic acid; [(1-{5-[4-({2-[(4-chlorophenyl)amino]-3,4-dioxocyclobut-1 -en-1 -yl} amino)phenyl]-1,3-thiazol-2-yl} cyclobutyl)oxy]acetic acid; {[l-(5-{4-[(anilinocarbonyl)amino]phenyl}-4-methyl-1,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid; {[l-(4-methyl-5-{4-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyl}-1,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid; {[ l-(5- {6-[(anilinocarbonyl)amino]pyridin-3-yl} -4-methyl-1,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid; {[l-(4-methyl-5-{6-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)aniino]pyridin-3-yl}-1,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid; {[l-(5-{6-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amino]pyridin-3-yl}-l,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid; 2-{[l -(5- {6-[( {[3-(trifluoromethyl)phenyl]amino} carbonyl)amino]pyridin-3-yl}-1,3-thiazol-2-yl)cyclopentyl]oxy}propanoic acid; 2- {[ 1 -(5- {6-[(anilinocarbonyl)amino]pyridin-3-yl} -1,3-tiuazol-2-yl)cyclopentyl]oxy}propanoic acid; {[l-(5-{4-[(7-methyl-1,3-benzoxazol-2-yl)amino]phenyl}-1,3-thiazol-2-yl)cyclopentyl]oxy} acetic acid; N-{4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-1,3-thiazol-5-yl]phenyl}-2-[3-(trifluoromethyl)phenyl]acetamide; 2-(2,4-difluorophenyl)-N-{4-[2-(4-hydroxytetrahydro-2H-pyTan-4-yl)-1,3-thiazol-5-yl]phenyl} acetamide; 2-(2,5-difluorophenyl)-N-{4-[2-(4-hydroxytetrahydro-2H-pyran-4-yl)-1,3-thiazol-5-yl]phenyl} acetamide; [(1-{5-[4-(benzoylarnino)phenyl]-1,3-thiazol-2-yl}cyclobutyl)oxy]aceticacid; ({1-[5-(4- {[(3-fluorophenyl)acetyl]amino}phenyl)-1,3-thiazol-2-yl]cyclobutyl}oxy)acetic acid; ({l-[5-(4-{[4-(trifluoromethyl)benzoyl]amino}phenyl)-1,3-thiazol-2-yl]cyclobutyl}oxy)acetic acid; [(1-{5-[4-({[2-fluoro-5-(trifluoromethyl)phenyl]acetyl} arnino)phenyl]-1,3-thiazol-2-yl}cyclobutyl)oxy]acetic acid; {[l-(5-{6-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]pyridin-3-yl}-1,3-oxazol- 2-yl)cyclopentyl]oxy} acetic acid; ({l-[5-(4- {[(2,5-difluorophenyl)aceryl]amino}phenyl)-1,3-thiazol-2-yl]cyclobutyl}oxy)acetic acid; ({l-[5-(4-{[(3,5-difluorophenyl)acetyl]amino}phenyl)-1,3-thiazol-2- yl]cyclobutyl}oxy)acetic acid; ({l-[5-(4-{[(3,4-difluorophenyl)acetyl]amino}phenyl)-1,3-thiazol-2- yl]cyclobutyl}oxy)acetic acid; {[l-(4-{6-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]pyridin-3-yl}phenyl)cyclopentyl]oxy}aceticacid; 2-( 1 -(2-fluoro-4-(6-(3-(3-(trifluorometb.yl)phenyl)ureido)pyridin-3-yl)phenyl)cyclobutoxy)aceticacid; H5-(4-(4-oxa-l-azabicyclo[3.2.1]octan-5-yl)phenyl)pyridin-2-yl)-3-phenylurea; 2-(l-(3-fluoro-4-(6-(3-(3-(trifluoromethyl)phenyl)ureido)pyridin-3-yl)phenyl)cyclopentyloxy)acetic acid; 2-(l-(3-fluoro-4-(6-(3-(3-(trifluoromethyl)phenyl)ureido)pyridin-3-yl)phenyl)cyclobutoxy)acetic acid; [(l-{5-[4-({[(2-fluorophenyl)amino]carbonyl}amino)phenyl]pyridin-2-yl}cyclopentyl)oxy]acetic acid; [1-(4- {6-[( {[3-(trifluoromethyl)phenyl]aniino} carbonyl)amino]pyridin-3-yl}phenyl)cyclopentyl]aceticacid; (l-{4-[6-({[(2-fluorophenyl)amino]carbonyl}amino)pyridin-3-yl]phenyl} cyclopentyl)acetic acid; {[l-(2-fluoro-4-{6-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]pyridin-3-yl}phenyl)cyclobutyl]oxy} acetic acid; [(l-{2-fluoro-4-[6-({[3-(trifluoromethyl)phenyl]acetyl}amino)pyridin-3-yl]phenyl}cyclobutyl)oxy]acetic acid; and {[1-(3-£luoro-4'- {[6-(trifluoromethoxy)-1,3 -benzothiazol-2-yl]amino} -1,1 '-biphenyl-4-yl)cyclobutyl]oxy} acetic acid; or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. 13. A method for treating a disorder selected from the group consisting of type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease, said method comprising the step of administering to a subject in need thereof a compound of claim 1, or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. 14. The method of claim 13 further comprising the step of co-administering with one or more pharmaceutical agents selected from the group consisting of DPPIV inhibitor, incretin mimetic, metformin, fenofibrate, rimonabant, sibutramine, orlistat, nicotinic acid, and a statin. 15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, in combination with a pharmaceutically acceptable carrier. 16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, one or more pharmaceutical agents selected from the group consisting of DPPIV inhibitor, incretin mimetic, metformin, fenofibrate, rimonabant, sibutramine, orlistat, a statin, and nicotinic acid, in combination with a pharmaceutically acceptable carrier. 17. A method for treating a disorder selected from the group consisting of type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease, said method comprising the step of administering to a subject in need thereof a pharmaceutical composition of claim 15. 18. A method for treating a disorder selected from the group consisting of type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease, said method comprising the step of administering to a subject in need thereof a pharmaceutical composition of claim 16.